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A B S T R A C T
Background
A key aim of asthma care is to empower each person to take control of his or her own condition. A personalised asthma action plan
(PAAP), also known as a written action plan, an individualised action plan, or a self-management action plan, contributes to this
endeavour. A PAAP includes individualised self-management instructions devised collaboratively with the patient to help maintain
asthma control and regain control in the event of an exacerbation. A PAAP includes baseline characteristics (such as lung function),
maintenance medication and instructions on how to respond to increasing symptoms and when to seek medical help.
Objectives
To evaluate the effectiveness of PAAPs used alone or in combination with education, for patient-reported outcomes, resource use and
safety among adults with asthma.
Search methods
We searched the Cochrane Airways Group Specialised Register of trials, clinical trial registers, reference lists of included studies and
review articles, and relevant manufacturers’ websites up to 14 September 2016.
Selection criteria
We included parallel randomised controlled trials (RCTs), both blinded and unblinded, that evaluated written PAAPs in adults with
asthma. Included studies compared PAAP alone versus no PAAP, and/or PAAP plus education versus education alone.
Data collection and analysis
Two review authors independently extracted study characteristics and outcome data and assessed risk of bias for each included study.
Primary outcomes were number of participants reporting at least one exacerbation requiring an emergency department (ED) visit or
hospitalisation, asthma symptom scores on a validated scale and adverse events (all causes). Secondary outcomes were quality of life
measured on a validated scale, number of participants reporting at least one exacerbation requiring systemic corticosteroids, respiratory
function and days lost fromwork or study.We used a random-effects model for all analyses and standard Cochrane methods throughout.
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Main results
We identified 15 studies described in 27 articles that met our inclusion criteria. These 15 included studies randomised a total of 3062
participants (PAAP vs no PAAP: 2602 participants; PAAP plus education vs education alone: 460 participants). Ten studies (eight
PAAP vs no PAAP; two PAAP plus education vs education alone) provided outcome data that contributed to quantitative analyses.
The overall quality of evidence was rated as low or very low.
Fourteen studies lasted six months or longer, and the remaining study lasted for 14 weeks. When reported, mean age ranged from 22
to 49 years and asthma severity ranged from mild to severe/high risk.
PAAP alone compared with no PAAP
Results showed no clear benefit or harm associated with PAAPs in terms of the number of participants requiring an ED visit or
hospitalisation for an exacerbation (odds ratio (OR) 0.75, 95%confidence interval (CI) 0.45 to 1.24; 1385 participants; five studies; low-
quality evidence), change from baseline in asthma symptoms (mean difference (MD) -0.16, 95% CI -0.25 to - 0.07; 141 participants;
one study; low-quality evidence) or the number of serious adverse events, including death (OR 3.26, 95% CI 0.33 to 32.21; 125
participants; one study; very low-quality evidence). Data revealed a statistically significant improvement in quality of life scores for
those receiving PAAP compared with no PAAP (MD 0.18, 95% CI 0.05 to 0.30; 441 participants; three studies; low-quality evidence),
but this was below the threshold for a minimum clinically important difference (MCID). Results also showed no clear benefit or harm
associated with PAAPs on the number of participants reporting at least one exacerbation requiring oral corticosteroids (OR 1.45, 95%
CI 0.84 to 2.48; 1136 participants; three studies; very low-quality evidence) nor on respiratory function (change from baseline forced
expiratory volume in one second (FEV1): MD -0.04 L, 95% CI -0.25L to 0.17 L; 392 participants; three studies; low-quality evidence).
In one study, PAAPs were associated with significantly fewer days lost from work or study (MD -6.20, 95% CI -7.32 to - 5.08; 74
participants; low-quality evidence).
PAAP plus education compared with education alone
Results showed no clear benefit or harm associated with adding a PAAP to education in terms of the number of participants requiring an
ED visit or hospitalisation for an exacerbation (OR 1.08, 95% CI 0.27 to 4.32; 70 participants; one study; very low-quality evidence),
change from baseline in asthma symptoms (MD -0.10, 95% CI -0.54 to 0.34; 70 participants; one study; low-quality evidence), change
in quality of life scores from baseline (MD 0.13, 95% CI -0.13 to 0.39; 174 participants; one study; low-quality evidence) and number
of participants requiring oral corticosteroids for an exacerbation (OR 0.28, 95% CI 0.07 to 1.12; 70 participants; one study; very low-
quality evidence). No studies reported serious adverse events, respiratory function or days lost from work or study.
Authors’ conclusions
Analysis of available studies was limited by variable reporting of primary and secondary outcomes; therefore, it is difficult to draw
firm conclusions related to the effectiveness of PAAPs in the management of adult asthma. We found no evidence from randomised
controlled trials of additional benefit or harm associated with use of PAAP versus no PAAP, or PAAP plus education versus education
alone, but we considered the quality of the evidence to be low or very low, meaning that we cannot be confident in the magnitude or
direction of reported treatment effects. In the context of this caveat, we found no observable effect on the primary outcomes of hospital
attendance with an asthma exacerbation, asthma symptom scores or adverse events. We recommend further research with a particular
focus on key patient-relevant outcomes, including exacerbation frequency and quality of life, in a broad spectrum of adults, including
those over 60 years of age.
P L A I N L A N G U A G E S U M M A R Y
Written and personalised action plans to help adults manage their asthma
Review question
People with asthma may be given a written personalised action plan for managing their asthma. This plan provides information on
which medicines they should take and when. Other people may be given education on how they should look after their asthma. This
review set out to see if using a plan on its own or with education helps improve outcomes for people with asthma.
Background
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Asthma is a disease that affects the lungs, which can make it difficult for people to breathe. Some people can manage their asthma very
well, and it does not affect them very much, but for other people, asthma can change and sometimes can get worse very quickly and
often. When this happens, people may go to see their doctor or may go to the hospital. When their asthma gets worse, people can take
medicines or can change the amount of medicine they take to make their asthma better. To know when and how they should change
their medicines, adults with asthma can be given a written plan that is designed just for them. This is called a personalised asthma
action plan (PAAP). The PAAP will tell people when they need to see their doctor and may include education on how they should
manage their asthma.
Study characteristics
We searched for studies up to September 2016. We found 15 studies that provided the information we were looking for in conducting
this review. A total of 3062 people had taken part in these studies; 2602 people took part in 11 studies looking at PAAP versus no
PAAP, and 460 people were included in four studies looking at PAAP and education versus just education. Fourteen studies lasted six
months or longer. The average age of people in these studies ranged from 22 to 49 years. Asthma severity ranged from mild to severe.
We were able to use data from 10 of these 15 studies to inform our findings.
Key results
PAAP alone compared with no PAAP: People using a PAAP did not show any difference (good or bad) in terms of having to go to
the hospital because their asthma worsened compared with people not using a PAAP. This result was the same for changes in asthma
symptom scores and number of deaths due to asthma. People with a PAAP showed no improvement in their quality of life compared
with those without a PAAP, but the difference was not large enough to be meaningful.
PAAP plus education compared with education alone: Review authors found no real difference - good or bad - between people using a
PAAP and education and those just receiving education. This finding was the same for all outcomes, that is, having to go to the hospital
because their asthma worsened and changes in symptom scores and quality of life.
Quality of the evidence
We rated the quality of the 15 included studies as low or very low because the few studies included in this review had problems with
study design, including how to enrol people into the study and how to handle missing data for some people. Also, studies had problems
with how outcome data for those who did not finish the study should be managed. This means that as future studies are completed
and added to future versions of this review, the findings of the review may change.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
PAAP compared with no PAAP for adults with asthma
Patient or population: adults with asthma
Setting: primary care, secondary care, tert iary care, community
Intervention: PAAP
Comparison: no PAAP
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with no PAAP Risk with PAAP
Exacerbat ion requiring
ED or hospitalisat ion.
Follow-up: range 14
weeks to 6 months.
82 per 1000. 63 per 1000
(39 to 100)
OR 0.75
(0.45 to 1.24)
1385
(5 RCTs)
⊕⊕©©
LOWa
No clear benef it or harm
of a PAAP (low-quality
evidence).
Asthma control, change
f rom baseline in ACQ.
Mean asthma control,
change f rom baseline in
ACQ was -0.29.
MD 0.16 lower
(0.25 lower to 0.07
lower)
- 141
(1 RCT)
⊕⊕©©
LOWb
No clear benef it or harm
of a PAAP (low-qual-
ity evidence); MCID for
ACQ was 0.5
Serious adverse events
(including deaths).
16 per 1000. 49 per 1000
(5 to 538)
OR 3.26
(0.33 to 32.21)
125
(1 RCT)
⊕©©©
VERY LOWc
No clear benef it or harm
of a PAAP (very low-
quality evidence)
Quality of lif e, change
f rom baseline in AQLQ.
Mean quality of lif e,
change f rom baseline in
AQLQ ranged f rom 0.1
to 0.91
MD 0.18 higher
(0.05 higher to 0.3
higher)
- 441
(3 RCTs)
⊕⊕©©
LOWd
Mean between-group
dif ference in improve-
ment f rom baseline did
not exceed the mini-
mum clinically impor-
tant dif f erence (0.5 for
AQLQ) and is unlikely to
be clinically relevant
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Exacerbat ion requiring
OCS.
306 per 1000. 390 per 1000
(270 to 523)
OR 1.45
(0.84 to 2.48)
1136
(3 RCTs)
⊕©©©
VERY LOWe
No clear benef it or harm
of a PAAP (low-quality
evidence).
Lung funct ion, change
f rom baseline in FEV1
(L).
Mean lung funct ion,
change f rom baseline in
FEV1 (L) was 0 L.
MD 0.04 L lower
(0.25 lower to 0.17
higher)
- 392
(3 RCTs)
⊕⊕©©
LOWf
No clear benef it or harm
of a PAAP (low-quality
evidence).
Days lost f rom work or
study.
Mean days lost f rom
work or study was 0.
MD 6.2 lower
(7.32 lower to 5.08
lower)
- 74
(1 RCT)
⊕⊕©©
LOWg
PAAP was associated
with signif icant ly fewer
days lost f rom work or
study
* The risk in the intervention group (and its 95% conf idence interval) is based on assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%
CI).
ACQ, Asthma Control Quest ionnaire; AQLQ, Asthma Quality of Life Quest ionnaire; CI, conf idence interval; ED, emergency department; FEV1, f orced expiratory volume in 1
second; GRADE, Grades of Recommendation, Assessment, Development and Evaluat ion Working Group; HR, hazard rat io; MCID, minimum clinically important dif f erence; MD,
mean dif ference; OCS, oral cort icosteroid; OR, odds rat io; PAAP, personalised asthma act ion plan; RCT, randomised controlled trial; RR, risk rat io
GRADE Working Group grades of evidence.
High quality: We are very conf ident that the true ef fect lies close to the est imate of ef fect.
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of ef fect but may be substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aThe quality of the evidence was downgraded once for risk of bias (3/ 5 studies at risk of attrit ion bias and baseline imbalance
in morbidity reported by Hoskins (weight 48.8%)) and once for imprecision (small number of total events; insuf f icient
sample size (opt imal size > 4 K) and CI including null ef fect and chance of appreciable benef it ).
bThe quality of the evidence was downgraded once for risk of bias (high risk of performance, detect ion and attrit ion bias) and
once for indirectness (based on only one study, thus reducing generalisability).
cThe quality of the evidence was downgraded once for risk of bias (attrit ion bias), once for imprecision (small number of
events, insuf f icient sample size and CI including null ef fect and appreciable risk of harm) and once for indirectness (single
study lim it ing generalisability).
dThe quality of the evidence was downgraded twice for risk of bias (performance, detect ion and attrit ion bias).
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eThe quality of the evidence was downgraded twice for risk of bias (attrit ion bias and baseline imbalance in morbidity reported
by Hoskins (weight 54.9%); high risk of other bias based on report ing error in Thoonen 2001) and once for imprecision (CI
including null ef fect and chance of appreciable benef it ).
f The quality of the evidence was downgraded once for risk of detect ion bias and attrit ion bias) and once for inconsistency
(opposite direct ion of ef fect observed in one study; heterogeneity I2 = 51%).
gThe quality of the evidence was downgraded twice for indirectness (single study lim it ing generalisability; study performed in
tert iary care sett ing in Serbia).
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Asthma is a common respiratory condition characterised by air-
way inflammation and oedema, bronchoconstriction and airflow
limitation. World Health Organization (WHO) estimates sug-
gest that up to 334 million people are affected worldwide, with
the majority of affected people living in low- and middle-income
countries (Global Asthma Report 2014); the total burden may
be greater than reported owing to the high prevalence of asthma
in countries that lack adequate reporting mechanisms. The eco-
nomic burden of asthma is considerable, with direct treatment
costs and indirect costs of lost productivity among the highest
for non-communicable diseases (Global Asthma Report 2014).
Symptoms including cough and breathlessness may be intermit-
tent or persistent (BTS/SIGN 2016). Triggers may be allergic (e.g.
pollen, animal dander, dust mite) or non-allergic (e.g. exercise,
smoking, cold air, smoke from fires in confined living spaces). The
disease may be characterised by repeated exacerbations requiring a
change to normal maintenance therapy. Treatment of people with
asthma includes avoidance of potential triggers (when possible),
use of inhaled corticosteroids (ICSs) and leukotriene receptor an-
tagonists (LTRAs) to reduce airway inflammation and use of in-
haled long-acting beta2-agonists (LABAs), short-acting beta2-ag-
onists (SABAs) and anticholinergic bronchodilators (i.e. long-act-
ing muscarinic antagonists (LAMAs)) to relieve airflow limitation
(BTS/SIGN 2016; GINA 2016; NICE 2007; NICE 2013). Ex-
acerbations may require the addition of oral or parenteral steroids.
People with severe asthma may also benefit from immunomodu-
latory therapy targeted to key mediators of allergic airway inflam-
mation, including immunoglobulin E (IgE) (Normansell 2014).
Goals of asthma treatment include total control of daytime and
nocturnal symptoms, normal exercise and functional capacity and
prevention of exacerbations (GINA 2016). It is clear from studies
including the national review of UK asthma deaths (NRAD 2014)
that there remains widespread misunderstanding of appropriate
asthma treatment on the part of both patients and healthcare pro-
fessionals; this puts people at risk of potentially avoidable adverse
outcomes. A key recommendation for enhancing asthma care in-
cludes empowering all individuals to take control of their own
condition and equipping them to deal with deteriorating symp-
toms early and appropriately (BTS/SIGN 2016).
Therefore, an important concept in asthma management is
supported self-management; a personalised asthma action plan
(PAAP) is a potentially important component of that support
(Pearce 2016). This plan should detail the person’s baseline charac-
teristics, including measures of control (e.g. peak expiratory flow
(PEF) and/or symptoms, and should state the agreed maintenance
medication. Such plans should also provide clear instruction on
how a person should respond to increasing symptoms, with the
aim of improving overall asthma control and minimising the risk
of exacerbations.
Description of the intervention
Historically, asthma action plans have been referred to by vari-
ous terms including written action plans, individualised action
plans and self-management action plans (Bhogal 2006). As op-
posed to a discrete intervention (Toelle 2011), PAAPs are con-
sidered an essential component of multi-faceted self-management
education (Bhogal 2006; BTS/SIGN 2016; GINA 2016; NICE
2013). Although the format and design of action plans may
vary (Charlton 1990; D’Souza 1996; Ducharme 2008; Jenkinson
1988; Kristiansen 2012; Marcano Belisario 2013; Turner 1998),
they are inherently similar in that they convey individualised self-
management instructions to enable people to both attain control
of asthma and regain control in the event of an acute exacerbation
(Bhogal 2006). For adults, PAAPs may be based on symptoms, on
peak flow monitoring or on both, whereas symptom-based plans
generally are preferable for children (BTS/SIGN 2016). Typically,
content includes objective cues to promote early detection of de-
teriorating asthma symptoms, medications prescribed and action
to take in the event of an acute episode, with particular reference
to step-up and step-down therapy, along with health service ac-
cess (Gibson 2004; Holt 2004; Partridge 2004; Toelle 2011). In
principle, individuals are not passive recipients of PAAPs (NICE
2013), as a participatory process is intended to maximise engage-
ment and ensure tailoring of the plan to a person’s experience
of asthma (Bauman 2003; Gibson 1995; Lahdensuo 1999; Ring
2011). PAAPs should be firmly embedded within the regular re-
view process (BTS/SIGN 2016) to record agreements made be-
tween clinician and patient. The modifiable nature of PAAPs is
intended to avoid ’prescribing’ of static care plans and to ensure
the co-production of contemporary self-care advice in the context
of the individual (Douglas 2002). In the present review, we will
focus on written PAAPs.
How the intervention might work
PAAPs primarily serve to promote self-management of asthma by
reminding people of their treatment plan and offering the fol-
lowing directives: which triggers to avoid, when to increase treat-
ment, how to increase treatment, how long to increase treatment
and when to seek medical help (Gibson 2004). By promoting and
increasing self-management of asthma, PAAPs ultimately aim to
improve a person’s overall control of his or her asthma symptoms.
PAAPs also function as an important communication tool for pa-
tients and healthcare professionals, representing both a record and
a reminder of discussions between patient and clinician (Bhogal
2006; Welsh 2011). They are individualised, enabling the under-
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lying nature of the person’s asthma to be taken into consideration
and reviewed on at least an annual basis (BTS/SIGN 2016).
Why it is important to do this review
The national review of UK asthma deaths highlighted that there
remain significant levels of avoidable morbidity (e.g. exacerbations
requiring oral steroids or admission to hospital) and death from
asthma (NRAD 2014). PAAPs are associated with better asthma
control in that they help reduce the risk of an exacerbation; for
people who have had a recent acute exacerbation resulting in ad-
mission to hospital, PAAPs may reduce re-admission rates (NICE
2013). Although both the Global Initiative for Asthma (GINA)
(GINA 2016) and British Thoracic Society (BTS)/Scottish Inter-
collegiate Guidelines Network (SIGN) (BTS/SIGN 2016) guide-
lines recommend that people are offered self-management educa-
tion, which should include a written PAAP, these recommenda-
tions are based on evidence from over a decade ago (Gibson 2004).
Moreover, BTS/SIGN guidelines identify gaps in the evidence on
which these guidelines were based. For example, data are insuffi-
cient for evaluation of the effectiveness of certain specific compo-
nents of written PAAPs related to corticosteroid use (BTS/SIGN
2016). Furthermore, debate continues as to the effectiveness of
written PAAPs in specific clinical settings (Khan 2014; Sheares
2015a), or when used alone or alongside education on self-man-
agement (Toelle 2011). Therefore, it is important that evidence
for the effectiveness of PAAPs is re-evaluated systematically to en-
sure that guidelines accurately reflect an up-to-date evidence base.
As PAAPs represent one component of multi-faceted self-man-
agement education, and given that provision of health education
generally represents a significant cost for hospitals and clinics, it
is important to confirm the effectiveness of PAAPs plus education
to ensure efficient use of limited resources.
O B J E C T I V E S
To evaluate the effectiveness of PAAPs used alone or in combina-
tion with education, for patient-reported outcomes, resource use
and safety among adults with asthma.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included parallel randomised controlled trials (RCTs), both
blinded and unblinded, of any duration evaluating written PAAPs
(for details, see Types of interventions). We included studies re-
ported as full text or published as abstract only and unpublished
data.
Types of participants
We included adults (aged 18 years or older) with asthma of any
severity.We required that the diagnosis of asthmabe determinedby
a clinician in accordance with validated national or international
guidelines (e.g. BTS/SIGN 2016; GINA 2016). We required that
studies that did not cite a specific guideline for diagnostic pur-
poses must provide adequate information to allow diagnosis by
review authors as per one of the validated guidelines. We excluded
participants with other respiratory comorbidities (e.g. bronchiec-
tasis, chronic obstructive pulmonary disease). If a study included
only a subset of relevant participants, we included that study only
if study authors could provide disaggregated data for participants
who meet review inclusion criteria.
Types of interventions
We noted significant variability in the content and format of ac-
tion plans (MacGillivray 2014).We defined a PAAP as any written
plan that enables people with asthma (or their carers) to recognise
when symptoms are worse, and that sets out actions to be taken
if asthma control should deteriorate. As per GINA 2016 guide-
lines, we required that PAAPs must include specific instructions
for patients (or their carers) regarding changes to reliever and con-
troller medications, ways that oral corticosteroids (OCSs) should
be used if needed and when and how healthcare services can be
accessed (GINA 2016). Thresholds for action as defined in these
plans could be based on symptoms or on peak flow. We assessed
the following comparisons.
1. PAAP alone versus no PAAP.
2. PAAP plus education intervention (defined per GINA 2016
guidelines) versus education intervention alone.
Types of outcome measures
Primary outcomes
1. Number of participants reporting at least one exacerbation
requiring emergency department visit or hospitalisation
2. Asthma symptom scores* (measured on a validated scale,
e.g. Asthma Control Questionnaire)
3. Adverse events (all-cause)
We selected the primary outcomes to represent an important mea-
sure of resource use, patient-reported outcomes and safety.
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Secondary outcomes
1. Quality of life (QoL)* (measured on a validated scale, e.g.
Asthma QoL Questionnaire)
2. Number of participants reporting at least one exacerbation
requiring systemic corticosteroids
3. Measure of respiratory function: forced expiratory volume
in one second (FEV1) or PEF
4. Days lost from work or study
Reporting one or more of the outcomes listed above was not an
inclusion criterion for this review.
Search methods for identification of studies
Electronic searches
We identified trials from the Cochrane Airways Trials Register,
which is maintained by the Information Specialist for the Group.
The Cochrane Airways Trials Register contains studies identified
from several sources.
1. Monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL), through the Cochrane Register
of Studies Online (crso.cochrane.org).
2. Weekly searches of MEDLINE Ovid SP (1946 to date).
3. Weekly searches of Embase Ovid SP (1974 to date).
4. Monthly searches of PsycINFO Ovid SP.
5. Monthly searches of the Cumulative Index to Nursing and
Allied Health Literature (CINAHL) EBSCO.
6. Monthly searches of the Allied and Complementary
Medicine Database (AMED) EBSCO.
7. Handsearches of the proceedings of major respiratory
conferences.
Studies contained in the Trials Register are identified through
search strategies based on the scope of Cochrane Airways. We have
provided details of these strategies, as well as a list of handsearched
conference proceedings, in Appendix 1. See Appendix 2 for search
terms used to identify studies for this review.
We searched the following trials registries.
1. US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov).
2. World Health Organization International Clinical Trials
Registry Platform (apps.who.int/trialsearch).
We searched the Cochrane Airways Trials Register and additional
sources from their inception to 14 September 2016 with no re-
striction on language of publication.
Searching other resources
We checked reference lists of all primary studies and review arti-
cles for additional references.We searched relevant manufacturers’
websites for trial information.
We searched for errata or retractions from included studies pub-
lished in full text on PubMed (www.ncbi.nlm.nih.gov/pubmed)
on 7 December 2016.
Data collection and analysis
Selection of studies
Two review authors (TG, AR or DE) independently screened titles
and abstracts of all studies identified for potential inclusion as
a result of the search, and coded them as ’retrieve’ (eligible or
potentially eligible/unclear) or ’do not retrieve’. We retrieved full-
text study reports/publications; two review authors (TG, AR, CM
or DE) independently screened the full text and identified studies
for inclusion. We identified and recorded reasons for exclusion of
ineligible studies. We resolved disagreements through discussion
or, if required, through consultationwith a third review author.We
identified and excluded duplicates and collatedmultiple reports of
the same study so that each study, rather than each report, was the
unit of interest in the review. We recorded the selection process in
sufficient detail to complete a PRISMA (Prefered Reporting Items
for Systematic Reviews and Meta-Analyses) flow diagram and a
Characteristics of excluded studies table.
Data extraction and management
We used a data collection form for study characteristics and out-
come data that was piloted on at least one study in the review.
Two review authors (AR, DE or CM) independently extracted the
following study characteristics from each of the included studies.
1. Methods: study design, total duration of study, details of
any ’run-in’ period, number of study centres and locations, study
setting, withdrawals and date of study.
2. Participants: number, mean age, age range, gender, severity
of condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria and exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications and excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected and time points reported.
5. Notes: funding for trial and notable conflicts of interest of
trial authors.
Two review authors (AR,DE,CMorTG) independently extracted
outcome data from each of the included studies. We noted in the
Characteristics of included studies table if outcome data were not
reported in a useable way.We resolved disagreements by consensus
or by consultation with a third review author. One review author
(DE) transferred data into Review Manager 5 (RevMan 2014).
We double-checked that data were entered correctly by comparing
data presented in the systematic review against the study reports.
A second review author (CM) performed a spot-check of study
characteristics against the trial report for accuracy.
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Assessment of risk of bias in included studies
Two review authors (AR, CM, DE or TG) independently assessed
the risk of bias for each study using the criteria outlined in the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011).We resolved disagreements by discussion or by consultation
with a third review author. We assessed risk of bias according to
the following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We graded each potential source of bias as high, low or unclear and
provided a quote from the study report together with a justification
for our judgement in the ’Risk of bias’ table. We summarised
risk of bias judgements across different studies for each of the
domains listed.We considered blinding separately for different key
outcomes when necessary (e.g. for unblinded outcome assessment,
risk of bias for all-cause mortality may be very different from
a participant-reported pain scale). When information on risk of
bias was related to unpublished data or to correspondence with a
trialist, we noted this in the ’Risk of bias’ table.
When considering treatment effects, we took into account the risk
of bias for studies that contributed to those outcomes.
Assessment of bias in conducting the systematic
review
We conducted the review according to the published protocol and
reported deviations from it in the Differences between protocol
and review section of the systematic review.
Measures of treatment effect
We analysed dichotomous data as odds ratios and as 95% confi-
dence intervals (CIs). We analysed continuous data as mean dif-
ferences and 95% CIs. We entered data presented as a scale with a
consistent direction of effect.We used change from baseline scores
when possible.
We undertookmeta-analyses only when this wasmeaningful (i.e. if
treatments, participants and the underlying clinical question were
similar enough for pooling to make sense).
We provided a narrative description of skewed data reported as
medians and interquartile ranges.
When multiple trial arms were reported in a single trial, we in-
cluded only the relevant arms. If two comparisons (e.g. interven-
tion A vs placebo and intervention B vs placebo) were combined in
the same meta-analysis, we halved the control group to avoid dou-
ble-counting. If trials reported outcomes at multiple time points,
we used the end of treatment time point.
Unit of analysis issues
For dichotomous outcomes, we used participants, rather than
events, as the unit of analysis (i.e. number of participants admit-
ted to hospital at least once rather than number of admissions per
participant).
Dealing with missing data
We contacted investigators or study sponsors to verify key study
characteristics and to obtain missing numerical outcome data
when possible (e.g. when a study was identified as abstract only).
When this was not possible, and when missing data were thought
to introduce serious bias, we explored the impact of including
such studies in the overall assessment of results by performing a
sensitivity analysis.
Assessment of heterogeneity
We used the I2 statistic to measure heterogeneity among the trials
in each analysis. If we identified substantial heterogeneity (i.e. I2 >
50%), we reported this and explored possible causes by performing
prespecified subgroup analysis.
Assessment of reporting biases
If we were able to pool 10 or more trials, we planned to create
and examine a funnel plot to explore possible small study and
publication biases.
Data synthesis
We used a random-effects model for all analyses, as we expected
variation in effects due to differences in study populations and
methods. We performed sensitivity analyses using a fixed-effect
model.
’Summary of findings’ table
We created a ’Summary of findings’ table using data from all seven
outcomes. We used the five GRADE considerations (study limi-
tations, consistency of effect, imprecision, indirectness and pub-
lication bias) to assess the quality of a body of evidence as it re-
lates to studies that contributed data to the meta-analyses for pre-
specified outcomes. We used methods and recommendations as
described in Section 8.5 and Chapter 12 of the Cochrane Hand-
book for Systematic Reviews of Interventions and used GRADEpro
software (Higgins 2011). We justified all decisions to downgrade
or upgrade the quality of studies by using footnotes, and we made
comments to aid the reader’s understanding of the review when
necessary.
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Subgroup analysis and investigation of heterogeneity
When possible, we planned to carry out the following subgroup
analyses for the primary outcomes.
1. People with recent unscheduled hospitalisation versus
people without.
2. Symptom-based versus peak flow-based PAAPs.
3. Use of single inhaler therapy (e.g. a single inhaler
containing LABA plus ICS used for both prevention and relief of
symptoms).
4. Treatment instructions individualised* using OCS only
versus not individualised by OCS only.
5. Treatment instructions individualised* using ICS versus not
individualised by ICS.
6. Treatment instructions individualised* using participant-
specific triggers versus not individualised by participant-specific
triggers.
7. Format of concurrent self-management education (if
applicable; e.g. subanalysis of the duration, format or frequency
of education).
8. Provider of self-management education (e.g. physician-led
vs nurse-led education).
*Individualisation of action plans was determined based on
whether plan templates include blank text boxes for participant-
specific asthma treatment instructions or asthma trigger details
(MacGillivray 2014).
We used the formal test for subgroup interactions provided in
Review Manager 5 (RevMan 2014).
Sensitivity analysis
We planned to carry out sensitivity analyses while excluding the
following.
1. Unpublished data (i.e. no peer-reviewed full-text paper
available).
2. Studies at high risk of bias for blinding.
R E S U L T S
Description of studies
We have reported details of included studies in the Characteristics
of included studies table and have provided a list of excluded stud-
ies (with reasons for exclusion) in the Characteristics of excluded
studies table.
Results of the search
Through searches of databases, we identified 1094 references
(Figure 1). After screening titles and abstracts, we excluded 998
references and sought full-text copies for the remaining 96 refer-
ences describing 78 studies. Of these, we excluded 66 full-text ar-
ticles describing 60 studies (see Excluded studies). The remaining
30 articles reported findings from the 18 studies included in this
review (15 included studies, 2 ongoing studies, 1 study awaiting
classification). We last updated all searches on 14 September 2016.
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Figure 1. Study flow diagram.
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Included studies
We included in the review 15 studies described in 27 articles.
Four of these studies are reported in multiple articles. Thus, for
example, three additional articles describe the study reported in
Evans 2005. These 15 included studies randomised a total of 3062
participants (PAAP vs no PAAP: n = 2602 participants; PAAP
plus education vs education alone: n = 460). Eleven studies were
relevant to the first comparison (PAAP vs no PAAP); eight studies
contributed data to the analyses (Ayres 1996; Cowie 1997; Sheares
2015;Hoskins 1996; Jones 1995;Milenkovi 2007;Nokela2010;
Thoonen 2001), and three provided no data of relevance to this
review (Baldwin 1995; Griffiths 2004; Wang 2004). We received
a communication just before submission indicating that relevant
data fromGriffiths 2004 are now available; if successfully sourced,
we will include these data in a subsequent update of the review.
Four studies were relevant to the second comparison (PAAP plus
education vs education alone); two studies contributed data to the
analyses (Charrois 2006; Klein 1998), and two provided no data
of relevance to this review (McArdle 1997; Sangha 2004).
Methods
Most (11) included studies were parallel-group randomised con-
trolled trials; four were cluster randomised trials for which the
primary care centre, rather than the participant, was the unit
of randomisation (Griffiths 2004; Hoskins 1996; Nokela 2010;
Thoonen 2001). Fourteen of the fifteen included studies were of
six months’ duration or longer (range six months to two years),
and one study had a duration of 14 weeks (Nokela 2010). Most
trials did not blind participants or personnel to treatment alloca-
tion, although blinding is not feasible with this intervention, and
assessor blinding was clearly reported in only two trials (Cowie
1997; Jones 1995). Studies were based in primary care (n = 7;
Baldwin 1995; Charrois 2006; Griffiths 2004; Hoskins 1996;
Jones 1995; Nokela 2010; Thoonen 2001), secondary care (n =
3; Cowie 1997; McArdle 1997; Sheares 2015), tertiary care (n =
3; Klein 1998; Milenkovi 2007; Wang 2004) or both primary
and secondary care (Ayres 1996), or study setting was not re-
ported (Sangha 2004). Trials were conducted in eight countries in-
cluding UK (Ayres 1996; Baldwin 1995; Griffiths 2004; Hoskins
1996; Jones 1995), USA (Sheares 2015), Canada (Charrois 2006;
Cowie 1997), the Netherlands (Klein 1998; Thoonen 2001),
Serbia (Milenkovi 2007), Hong Kong (Wang 2004), Australia
(McArdle 1997) and Sweden (Nokela 2010), or study location was
not reported (Sangha 2004).
Participants
We included studies that recruited adults aged 18 years of age and
older, or from which data for the adult population could be ob-
tained (Sheares 2015). Individual studies rarely reported the age
range of participants, but mean participant age ranged from 22
(Griffiths 2004) to 49 years (Milenkovi 2007), when reported.
Review authors classified asthma severity using a range of defini-
tions across the included studies and assigned participants across
the spectrum from mild to severe/high risk. Concomitant medi-
cations were infrequently reported.
Interventions
PAAP versus no PAAP
Nine studies assessed PAAPs that had components based on peak
flow (Ayres 1996; Baldwin 1995; Cowie 1997; Griffiths 2004;
Hoskins 1996; Jones 1995; Milenkovi 2007; Sheares 2015;
Thoonen 2001), one study assessed a PAAP based on symptoms
alone (Nokela 2010) and it was not possible to determine the na-
ture of the PAAP for one study that was reported only as an ab-
stract (Wang 2004).
PAAP plus education versus education alone
Three studies assessed PAAPs that had components based on peak
flow (Klein 1998; McArdle 1997; Sangha 2004), and the remain-
ing study (Charrois 2006) did not report the nature of the PAAP.
Educational components comprised ’generalised asthma educa-
tion’ (McArdle 1997); three consecutive weekly 90-minute ses-
sions provided by a specially trained asthma nurse covering the
pathophysiology of asthma, the role and side effects of medica-
tion, allergic and non-allergic triggers and symptoms indicating
an impending exacerbation (Klein 1998); a 45-minute discussion
with visual aids provided by the treating physician on the topic of
asthma pathophysiology (Sangha 2004); and an educational com-
ponent on the topic of ’all asthma medications’ (Charrois 2006).
Outcomes
Outcomes were not consistently reported across trials. Five stud-
ies that met the review inclusion criteria did not report relevant
outcomes (Baldwin 1995; Griffiths 2004; McArdle 1997; Sangha
2004; Wang 2004); when it was reasonable that relevant data
may have been collected, we requested data from the trial authors
(Griffiths 2004; McArdle 1997; Sangha 2004; Wang 2004); in all
cases but one (Griffiths 2004), study authors were not able to pro-
vide additional data or we received no response. For the primary
outcomes, six studies reported the proportion of participants who
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experienced an exacerbation requiring an emergency department
visit or hospitalisation (Ayres 1996; Charrois 2006; Cowie 1997;
Hoskins 1996; Milenkovi 2007; Nokela 2010); two studies re-
ported asthma control measured on a validated scale (Charrois
2006; Nokela 2010); and two studies reported serious adverse ef-
fects (Ayres 1996; Hoskins 1996). For the secondary outcomes,
four studies reported quality of life using the Asthma Quality
of Life Questionnaire (Klein 1998; Nokela 2010; Sheares 2015;
Thoonen 2001); four studies reported the number of participants
who experienced an exacerbation requiring treatment with OCSs
(Charrois 2006; Hoskins 1996; Jones 1995; Thoonen 2001); four
studies reported various measures of lung function (Ayres 1996;
Jones 1995; Milenkovi 2007; Thoonen 2001); and one study
reported days lost from work or study (Milenkovi 2007).
Excluded studies
We excluded 66 full-text articles related to 60 studies. We at-
tributed the high number of exclusions at full-text evaluation to
the fact that many abstracts/titles alluded to self-management pro-
grammes, but without consulting the full-text reports, it was diffi-
cult for review authors to ascertain whether these studies included
a PAAP. Of the 60 excluded studies, 29 did not include our se-
lected comparator (PAAP + education, or no PAAP and no ed-
ucation), 22 did not fulfil our definition of the intervention, six
used a study design that did not meet our inclusion criteria (i.e.
non-randomised or pseudo-randomised) and three did not meet
our population criteria (i.e. children only). We have provided ad-
ditional details in the Characteristics of excluded studies table.
Risk of bias in included studies
We have presented details of the risk of bias associated with each
study along with supporting evidence in the Characteristics of
included studies tables. Figure 2 presents a summary of risk of bias
judgements according to study and domain, and Figure 3 depicts
the risk of bias for each domain (see also following subsections)
across all included studies.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
All studies had low or unknown risk of selection bias. Six of the 15
included studies were associated with low risk of bias for random
sequence generation (Charrois 2006; Cowie 1997; Griffiths 2004;
Hoskins 1996; Nokela 2010; Sheares 2015), but the remaining
studies provided insufficient information. Four studies were asso-
ciated with low risk of bias in the allocation concealment process
(Charrois 2006; Cowie 1997; Klein 1998; Sheares 2015) but the
remaining studies did not provide sufficient information to inform
a rating. We considered no studies to be at high risk of selection
bias.
Blinding
We considered all included studies to be at high risk of perfor-
mance bias, but this was not a consequence of poor design, as
blinding of participants and personnel was not feasible for this in-
tervention. Performance-related outcome measures, such as peak
flow, asthma control and quality of life, may have been suscepti-
ble to detection bias. Outcomes such as exacerbations and serious
adverse events were less likely to be influenced by participants’ or
investigators’ knowledge of the intervention. We considered two
trials that blinded outcome assessment to be at low risk of po-
tential detection bias (Cowie 1997; Griffiths 2004); eight studies
provided insufficient information (detection bias unknown), and
we considered the remaining five studies to be at high risk of de-
tection bias (Ayres 1996; Baldwin 1995; Hoskins 1996; Nokela
2010; Thoonen 2001).
Incomplete outcome data
Seven studies had low risk of attrition bias; three others provided
insufficient information and we judged their risk of bias as un-
known. Five studies had high risk of attrition bias owing to in-
complete outcome data (Ayres 1996; Hoskins 1996; Jones 1995;
Nokela 2010; Sheares 2015).
Selective reporting
Three studies were at low risk of reporting bias (Charrois 2006;
Klein 1998; Sheares 2015). A publicly provided protocol was not
available for most studies, resulting in a judgement of ’unknown’
risk of reporting bias. We considered two studies to be at high risk
of reporting bias (Cowie 1997; Jones 1995).
Other potential sources of bias
We considered three studies to be at high risk of ’other’ bias. Phar-
macist compliance with the intervention was poor in Charrois
2006. This meant that only three-quarters of the intervention
group received awritten asthma action plan (WAAP), and less than
half of participants received education about WAAP at each phar-
macy visit. Hoskins 1996 reported a between-group imbalance in
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morbidity at baseline. Although these investigators reported some
outcome measures as changes from baseline, this was not the case
for all outcomes, and the magnitude or direction of treatment ef-
fect may have been affected. Thoonen and colleagues noted that
participantswho receivedPAAPswere providedwith anoral course
of prednisolone, and that this prescription may have been incor-
rectly interpreted as evidence of use of prednisolone during an
exacerbation; thus data on exacerbations requiring treatment with
an OCS may overestimate the number of participants with an ex-
acerbation requiring an OCS in the PAAP group compared with
the control group (Thoonen 2001).We considered three studies to
have unknown risk of ’other’ bias because it was not clear whether
imbalance in baseline characteristics between groups would affect
outcomes (Griffiths 2004; Nokela 2010; Sheares 2015). We con-
sidered the remaining included studies to have low risk of ’other’
bias.
Effects of interventions
See: Summary of findings for the main comparison PAAP
compared with no PAAP for adults with asthma; Summary of
findings 2 PAAP plus education compared with education alone
for adults with asthma
PAAP versus no PAAP
Primary outcomes
Number of participants reporting at least one exacerbation
requiring emergency department visit or hospitalisation
Five studies involving 1385 participants found no statistically sig-
nificant difference in the number of exacerbations requiring an
emergency department (ED) visit or hospitalisation between those
participants receiving PAAP and those not receiving PAAP (odds
ratio (OR) 0.75, 95%confidence interval (CI) 0.45 to 1.24) (Anal-
ysis 1.1). Among those who used a PAAP (vs no PAAP), we es-
timated that 19 fewer people per 1000 would have an exacerba-
tion requiring an ED visit/hospitalisation, but confidence inter-
vals ranged from 43 fewer to 18 more. We observed a low level
of heterogeneity for this outcome (I2 = 17%). Three studies mea-
sured this outcome at six months, and the remaining two studies
measured this outcome at three months and 12months. The qual-
ity of the evidence was low, as we had downgraded it once for risk
of bias (3/5 studies at risk of attrition bias and baseline imbalance
in morbidity as reported by Hoskins 1996 (weight 48.8%) and
once for imprecision (small total number of events; sample size
insufficient (optimal size > 4K) and confidence intervals include
null effect and chance of appreciable benefit).
Asthma symptom scores
One study of 141 participants assessed change from baseline on
the AsthmaControlQuestionnaire and reported amean difference
(MD) of -0.16 (95%CI -0.25 to -0.07) (Analysis 1.2). The quality
of the evidence was low, as we had downgraded it once for risk of
bias (high risk of performance, detection and attrition bias) and
once for indirectness (based on only one study, therefore limiting
generalisability).
Serious adverse events (including death)
Two studies contributed data on serious adverse events (SAEs),
including deaths (Ayres 1996; Hoskins 1996). However, the SAEs
reported in Hoskins 1996 comprised deaths that were considered
unrelated to asthma. Therefore, we did not combine these events
with data onSAEs fromAyres 1996.Results showedno statistically
significant differences in SAEs between participants receiving a
PAAP and those not receiving a PAAP (OR 3.26, 95% CI 0.33 to
32.21; 125 participants; one study) (Analysis 1.3). Among those
who used a PAAP (vs no PAAP), we estimated that 33more people
per 1000 would have an SAE; confidence intervals ranged from 11
fewer to 522 more. We considered the quality of the evidence to
be very low, as we had downgraded it once for risk of bias (attrition
bias), once for imprecision (few events, insufficient sample size
and CI, including null effect and appreciable risk of harm) and
once for indirectness (limited generalisability of single study).
Secondary outcomes
Quality of life
We analysed data from three studies with 441 participants that
assessed change in score from baseline on the Asthma Quality of
Life Questionnaire (AQLQ) and found statistically significant im-
provement in quality of life scores for those receiving a PAAP com-
pared with those not receiving a PAAP (mean difference (MD)
0.18, 95% CI 0.05 to 0.30) (Analysis 1.4). However, the magni-
tude of theMDwas lower than the establishedminimumclinically
important difference (MCID 0.5) and is thus unlikely to be of
clinical relevance. We noted a moderate level of heterogeneity (I2
= 61%). Each study measured outcomes at a different time point,
namely, three months, 12 months and 24 months post recruit-
ment. The quality of the evidence was low, as we had downgraded
it twice for risk of bias (performance, detection and attrition bias).
Number of participants reporting at least one exacerbation
requiring systemic corticosteroids
We analysed data from three studies involving 1136 participants
and found that use of PAAP had no significant effect on the num-
ber of participants reporting at least one exacerbation requiring
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oral systemic corticosteroids (OR 1.45, 95% CI 0.84 to 2.48)
(Analysis 1.5). We observed a moderate level of heterogeneity (I
2 = 50%). We considered the quality of the evidence to be very
low, as we had downgraded it twice for risk of bias (attrition bias
and baseline imbalance in morbidity as reported by Hoskins 1996
(weight 54.9%); other risk of bias based on a reporting error in
the study reported by Thoonen 2001) and once for imprecision
(CI including null effect and chance of appreciable benefit).
Measures of respiratory function
Results showed no statistically significant difference in change in
FEV1 from baseline when groups receiving PAAP were compared
with those not receiving PAAP (MD-0.04, 95%CI -0.25 to 0.17);
we notedmoderate heterogeneity (I2 = 50%) (Analysis 1.6). Three
studies with a total of 392 participants assessed this outcome. The
quality of the evidence was low, as we had downgraded it once
for risk of bias (detection bias and attrition bias) and once for
inconsistency (opposite direction of effect observed in one study).
Data from two studies (146 participants) showed no statistically
significant difference in the change from baseline of % predicted
FEV1 when the PAAP group was compared with the non-PAAP
group (MD 0.40, 95% CI -6.05 to 6.85) (Analysis 1.7). Findings
show no heterogeneity (I2 = 0%), and the quality of the evidence
was low, as we had downgraded it once for risk of bias (attrition
and reporting bias) and once for inconsistency (opposite direction
of effect).
One study of 72 participants assessed change from baseline in %
predicted PEF and found no difference between the two groups
(MD 1.20, 95% CI -5.67 to 8.07) (Analysis 1.8). The quality of
the evidence was low, as we had downgraded it once for risk of bias
(performance, attrition and reporting) and once for indirectness
(limited generalisability of single study).
Similarly, one studymeasured change frombaseline in PEF among
a total of 125 participants and found no difference between the
group receiving PAAP and the group not receiving PAAP (MD -
18.00, 95% CI -54.03 to 18.03) (Analysis 1.9). The quality of the
evidence was very low, as we had downgraded it once for risk of bias
(attrition bias), once for indirectness (limited generalisability of
single study) and once for imprecision (wide confidence intervals
encompassing 72 L/min).
Days lost from work or study
One study counted days lost from work or study and found that
the 37 participants receiving PAAP had a significant reduction in
the number of days lost comparedwith the 37 participantswhodid
not receive PAAP (MD -6.20, 95% CI -7.32 to -5.08) (Analysis
1.10). The quality of the evidence was low, as we had downgraded
it twice for indirectness (limited generalisability of single study;
study performed in tertiary care setting in Serbia).
Subgroup analyses
As per the protocol, we intended to performprespecified subgroup
analyses on the primary outcomes. The outcome ’number of par-
ticipants reporting at least one exacerbation requiring emergency
department visit or hospitalisation’ was the only primary outcome
for which a sufficient number of studies contributed data to permit
subgroup analysis. The following subgroup analyses were not fea-
sible because insufficient information was provided in published
reports or reporting of key variables was inconsistent: people with
recent unscheduled hospitalisation versus people without (infor-
mation not reported by all contributing studies); symptom-based
versus peakflow-based plans (all studies used peakflow-based plans
or the type of plan was not reported); use of single-inhaler therapy
(not reported by any included study); treatment instructions in-
dividualised using OCS/ICS/participant-specific triggers (incon-
sistently reported across included studies). The final two planned
subgroup analyses (format of concurrent self-management edu-
cation; provider of concurrent self-management education) were
not relevant to this comparison.
Sensitivity analyses
The outcome ’number of participants reporting at least one exac-
erbation requiring emergency department visit or hospitalisation’
was the only outcome with a sufficient number of contributing
studies to permit the prespecified sensitivity analyses. However, no
prespecified sensitivity analyses were feasible because unpublished
data did not contribute to this outcome, all studies contributing
data to this outcome were assessed as having high risk of perfor-
mance bias and only one study was assessed as having low risk of
detection bias (Cowie 1997).
PAAP plus education intervention (defined per GINA
2015 guidelines) versus education intervention alone
Primary outcomes
Number of participants reporting at least one exacerbation
requiring emergency department visit or hospitalisation
One study assessed exacerbations requiring an emergency depart-
ment visit or hospitalisation and found no difference between the
group receiving PAAP and group receiving education alone (OR
1.08, 95% CI 0.27 to 4.32; 70 participants; one study) (Analysis
2.1). For people who used a PAAP plus education (vs education
alone), we estimated that 15 more people per 1000 would have
an exacerbation requiring an emergency department visit/hospi-
talisation, but confidence intervals ranged from 176 fewer to 344
more. The quality of the evidence was very low, as we had down-
graded it once for risk of bias (’other’: participants did not receive
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the intervention as planned), once for indirectness (limited gener-
alisability of single study) and once for imprecision (CI including
null effect and risk of appreciable harm or benefit).
Asthma symptom scores
One study of 70 participants evaluated change in score on the
Asthma Control Questionnaire from baseline and found no dif-
ference between the group receiving PAAP with an educational
intervention and the group receiving education alone (MD -0.10,
95% CI -0.54 to 0.34; 70 participants; one study) (Analysis 2.2).
The quality of the evidence was low, as we had downgraded it once
for risk of bias (’other’: participants did not receive the interven-
tion as planned) and once for indirectness (limited generalisability
of single study).
Serious adverse events (including death)
No studies reported data for this outcome.
Secondary outcomes
Quality of life
No difference was found in changes in score from baseline on
the Asthma Quality of Life Questionnaire between a group of
84 participants receiving PAAP and education and a group of 90
participants in the same study receiving education alone (MD
0.13, 95%CI -0.13 to 0.39; 174 participants; one study) (Analysis
2.3). The quality of the evidence was low, as we had downgraded it
once for risk of bias (’performance bias) and once for indirectness
(limited generalisability of single study).
Number of participants reporting at least one exacerbation
requiring systemic corticosteroids
One study that assessed use of PAAP and education compared
with education alone found no statistically significant differences
between groups in terms of the number of participants reporting at
least one exacerbation requiring oral systemic corticosteroids (OR
0.28, 95% CI 0.07 to 1.12; 70 participants; one study) (Analysis
2.4). The quality of the evidence was very low, as we had down-
graded it once for risk of bias (’other’: participants did not receive
the intervention as planned), once for indirectness (limited gener-
alisability of single study) and once for imprecision (CI including
null effect and risk of appreciable benefit).
Measures of respiratory function
No studies reported data for this outcome.
Days lost from work or study
No studies reported data for this outcome.
Subgroup and sensitivity analyses
For this comparison, the number of studies contributing data to
any of the primary outcomes was insufficient to permit subgroup
or sensitivity analyses.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
PAAP plus education compared with education alone for adults with asthma
Patient or population: adults with asthma
Setting: Community, secondary care, tert iary care
Intervention: PAAP plus educat ion
Comparison: educat ion alone
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with education
alone
Risk with PAAP plus
education
Exacerbat ion requiring
ED or hospitalisat ion.
265 per 1000. 280 per 1000
(89 to 609)
OR 1.08
(0.27 to 4.32)
70
(1 RCT)
⊕©©©
VERY LOWa
No clear benef it or harm
of PAAP plus educa-
t ion (very low-quality
evidence). Risk with ed-
ucat ion alone based on
12 months before study
start
Asthma control, change
f rom baseline in ACQ
score.
Mean asthma control,
change f rom baseline in
ACQ score was -0.29
MD 0.1 lower
(0.54 lower to 0.34
higher)
- 70
(1 RCT)
⊕⊕©©
LOWb
No clear benef it or harm
of PAAP plus educat ion
(low-quality evidence).
MCID for ACQ (0.5) not
reached
Serious adverse events
(including death).
Included studies reported no data for this outcome.
Quality of lif e, change
f rom baseline in AQLQ
score.
Mean quality of lif e,
change f rom baseline in
AQLQ score was 0.3
MD 0.13 higher
(0.13 lower to 0.39
higher)
- 174
(1 RCT)
⊕⊕©©
LOWc
No clear benef it or harm
of PAAP plus educat ion
(low-quality evidence).
MCID for AQLQ (0.5)
not reached
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Exacerbat ion requiring
OCS.
324 per 1000. 118 per 1000
(32 to 349)
OR 0.28
(0.07 to 1.12)
70
(1 RCT)
⊕©©©
VERY LOWd
No clear benef it or harm
of PAAP plus educa-
t ion (very low-quality
evidence). Risk with ed-
ucat ion alone based on
12 months before study
start
Lung funct ion. Included studies reported no data for this outcome.
Days lost f rom work or
study.
Included studies reported no data for this outcome.
* The risk in the intervention group (and its 95% conf idence interval) is based on assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%
CI).
ACQ, Asthma Control Quest ionnaire; AQLQ, Asthma Quality of Life Quest ionnaire; CI, conf idence interval; ED, emergency department; GRADE, Grades of Recommendation,
Assessment, Development and Evaluat ion Working Group; HR, hazard rat io; MCID, minimum clinically important dif f erence; MD, mean dif ference; OCS, oral cort icosteroid; OR,
odds rat io; PAAP, personalised asthma act ion plan; RCT, randomised controlled trial; RR, risk rat io
GRADE Working Group grades of evidence.
High quality: We are very conf ident that the true ef fect lies close to the est imate of ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of ef fect but may be substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aThe quality of the evidence was downgraded once for risk of bias (’other’: Part icipants did not receive the intervent ion as
planned), once for indirectness (single study reducing generalisability) and once for imprecision (CI including null ef fect
and risk of appreciable harm or benef it ).
bThe quality of the evidence was downgraded once for risk of bias (’other’: Part icipants did not receive the intervent ion as
planned) and once for indirectness (single study reducing generalisability).
cThe quality of the evidence was downgraded once for risk of bias (performance bias) and once for indirectness (single study
reducing generalisability).
dThe quality of the evidence was downgraded once for risk of bias (’other’: Part icipants did not receive the intervent ion as
planned), once for indirectness (single study reducing generalisability) and once for imprecision (CI including null ef fect and
risk of appreciable benef it ).
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D I S C U S S I O N
Summary of main results
Of the 15 studies included in this review, 10 provided data rele-
vant for analyses. Of these 10, eight studies compared a person-
alised asthma action plan (PAAP) versus no PAAP, and two studies
compared PAAP plus education versus education alone. For both
comparisons, our primary outcomes were the number of partici-
pants reporting at least one exacerbation requiring an emergency
department visit or hospitalisation, change in asthma symptom
scores and serious adverse events, including death. Secondary out-
come measures were change in quality of life scores, number of
exacerbations requiring oral corticosteroids, change in respiratory
function tests and number of days lost from work or study.
PAAP versus no PAAP
Data on exacerbations requiring emergency department atten-
dance or hospitalisation were available for five studies with 1385
participants. The meta-analysis did not show a statistically signif-
icant effect of the PAAP intervention on exacerbations, but this
is not considered strong evidence of no effect, as follow-up mea-
surement intervals were inconsistent (3 to 12 months), event fre-
quencies were very low in three trials and overall methodological
quality was relatively low.
Data from a validated asthma symptom score was available from
only one study with 141 participants, which reported a statisti-
cally significant mean difference (MD) of -0.16 (95% confidence
interval (CI) -0.25 to -0.07) in scores from the Asthma Control
Questionnaire, although this is below the 0.5 threshold for a mini-
mum clinically important difference and we considered the overall
quality of the evidence to be low.
Adverse events data were available from two studies with 441 par-
ticipants, butwe excluded one from the analyses, as reported deaths
were not asthma related (Hoskins 1996). Results showed no signif-
icant difference in serious adverse events reported in Ayres 1996,
but this finding was based on a very low event frequency (four),
making it difficult for review authors to draw firm conclusions.
Three studies contributed data on quality of life from the Asthma
Quality of Life Questionnaire (AQLQ). PAAPwas associated with
a statistically significant improvement in quality of life, but the
mean difference in score of 0.18 was below the minimum thresh-
old of 0.5 considered clinically relevant (low-quality evidence).
Three studies contributed data on exacerbations requiring oral
corticosteroids, but the effect was not statistically significant (very
low-quality evidence). Four studies provided data on measures of
respiratory function including forced expiratory volume in one
second (FEV1), FEV1 % predicted, peak expiratory flow (PEF)
and PEF% predicted, but effects were not statistically or clinically
significant (low-quality evidence). One study with 74 participants
showed a significant reduction in days lost from work with the
intervention (MD -6.2 days, 95%CI -7.32 to -5.08) but the qual-
ity of evidence was low. The low or very low quality of evidence
limits our capacity to draw firm conclusions based on secondary
outcomes.
PAAP plus education versus education intervention
alone
Only one study provided data on exacerbations requiring an emer-
gency department visit or hospitalisation (Charrois 2006) and
found no evidence of a significant difference. This same study
reported no significant difference in AQLQ scores, although we
considered the quality of evidence from this study to be low. No
studies reported data on adverse events.
One study reported no significant differences in change in AQLQ
scores (low-quality evidence), and one study reported no signif-
icant differences in exacerbations requiring oral corticosteroids,
although again, this finding was based on low-quality evidence.
No data were available for measures of respiratory function nor
for days lost from work or study.
In summary, our analyses were unable to demonstrate significant
benefit or harm associated with use of a PAAP, with or without an
educational component, for our primary outcomes. However, the
overall low quality of the evidence precludes robust conclusions
on the role of PAAP in adult asthma.
Overall completeness and applicability of
evidence
Although 15 studies met the inclusion criteria, only 10 included
outcomes relevant to the review and half of these were considered
to have high risk bias owing to incomplete outcome data (Ayres
1996; Hoskins 1996; Jones 1995; Nokela 2010; Sheares 2015).
For studies that contributed data, of the 2497 randomised par-
ticipants (n = 2152 PAAP vs no PAAP; n = 315 PAAP plus ed-
ucation vs education alone), 284 did not complete the trial (n =
257 PAAP vs no PAAP; n = 27 PAAP plus education vs educa-
tion alone). In studies for which details of withdrawal were given
for each study group (PAAP vs no PAAP) (Ayres 1996; Cowie
1997; Hoskins 1996; Milenkovi 2007; Nokela 2010; Sheares
2015; Thoonen 2001), rates tended to be higher in the interven-
tion arms. Study duration appeared to have no effect. Data from
Hoskins 1996 showed that when general practitioners (GPs) were
randomised to intervention and comparison arms (i.e. a cluster
randomised trial), a much higher percentage of GPs in the com-
parator arm compared with those issuing PAAPs returned data
on participants with asthma (83% vs 51%). The newly updated
British Thoracic Society (BTS)/Scottish IntercollegiateGuidelines
Network (SIGN) guidelines (BTS/SIGN 2016) and evidence pre-
sented in Ring 2011 and Pinnock 2015 highlight that successful
implementation of effective self-management interventions is as-
sociated with empowered patients and knowledgeable staff work-
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ing within an organisational culture that promotes asthma self-
management; this can be particularly challenging in primary care.
Hoskins 1996 may indicate that GP/patient compliance with the
intervention was poor.
The BTS/SIGN asthma guidelines issued since 2008 and the Na-
tional Institute for Clinical Excellence (NICE) Quality Standard
for Asthma (NICE 2013) recommend provision of PAAPs (as
opposed to verbal instructions alone) along with structured ed-
ucation, yet most studies contributing data to this review (n =
10), including the most recent study (Nokela 2010), did not in-
clude education as a comparator (n = 8). This suggests that recent
empirical research has not addressed guideline recommendations.
For the two older studies that featured education as a comparator
(Charrois 2006; Klein 1998), data could not be pooled owing to
lack of homogeneity in outcome measures.
Powell 2002 reported significant improvement in outcomes with
self-monitoring based on peak expiratory flow or symptom con-
trol plus regular review, but only two studies in this review used a
symptom-based PAAP and evidence may be insufficient to show
effectiveness. Heterogeneity was considerable with respect to the
structure/format of the PAAP used across studies, although we
were generally satisfied that the PAAPs used in the included studies
conformed to the key features described in BTS/SIGN guidelines
(BTS/SIGN 2016). As further discussed later, whether partici-
pants were provided with a course of oral corticosteroids (OCSs)
for self-administration on the basis of a predefined threshold of
symptoms or lung function potentially confounds our findings,
and included studies varied as to whether OCSs were provided for
self-administration, or whether participants were required to seek
medical consultation for OCS treatment.
Studies reported considerable variation in methods used to assess
asthma severity during recruitment that may have influenced dif-
ferences between study arms and between trials, owing to unequal
distribution of asthma severity among participants, which in turn
may have offered greater opportunity for improvement in more
severe cases. In Ayres 1996, participants who were self-managed
had better lung function and asthma severity scores at baseline
than those managed by their physician. Furthermore, a predefined
criterion required that we should exclude studies that enrolled pa-
tients with respiratory comorbidities (e.g. chronic obstructive pul-
monary disease (COPD)); thus the applicability of current find-
ings must be considered in this context.
All studies reported themean age of participants (one reported age
range), suggesting that adults 60 years of age and older are under-
represented, although this is a common feature of asthma research
(BTS/SIGN 2016).
Finally, it is important to acknowledge that the outcomes examined
in this review included elements commonly specified in PAAPs
(e.g. use of OCS, visit to the emergency department). This poten-
tially confounds the findings of included studies and could result
in an underestimation of the efficacy of PAAPs, because individ-
uals who received a PAAP would be more likely to experience a
given event (e.g. exacerbation requiring OCS use) compared with
individuals in the control group if the related intervention (e.g.
OCS) was prespecified in the action plan. In this respect, it is
possible that the outcome ’exacerbations requiring treatment with
OCS’ functions as a measure of self-management, whereby par-
ticipants take action to treat an exacerbation, rather than relying
on inhaled medicines or going to the emergency department. Ad-
ditionally, we noted heterogeneity between studies with respect to
provision of an ’OCS rescue pack’ (intended to be taken as laid
out in the personalised plan). For these reasons, we have elected
to refrain from presenting results for the OCS-related outcome in
terms of absolute numbers, which could be misleading. However,
despite these limitations, the selected outcomes examined in this
review represent commonly used measures of efficacy and safety
in randomised controlled trials of participants with asthma, and it
may be difficult to assess the effectiveness of PAAPs without using
these outcomes.
Quality of the evidence
We judged that three of the 15 included studies had low risk
of selection bias (Charrois 2006; Cowie 1997; Griffiths 2004)
and that all other studies poorly documented some aspect of the
selection process, leading to our determination that risk of bias
for these studies was unclear. Risk of performance bias for all 15
studies was high owing to study design and the self-management
intervention. We judged two studies to have low risk of detection
bias andfive tohave high risk, and riskwas unclear in the remaining
eight studies. We also judged five studies to be at high risk of
attrition bias, three others to be at unclear risk and the remaining
seven studies to be at low risk. We judged two studies to be at
high risk of reporting bias, three studies at low risk and 10 studies
at unclear risk. We had significant concerns about other forms of
bias in three studies. In summary, risk of bias was highly variable
between studies.
We rated the overall quality of the evidence as lowor very low inour
GRADE assessment, which takes into account risk of bias (study
limitations), as well as indirectness, imprecision, consistency of
effect and risk of publication bias. This rating was largely due
to high risk of bias as well as issues related to imprecision and
indirectness. It was not clear whether publication bias was an issue
because studies were insufficient for a formal assessment.
Potential biases in the review process
We conducted the review according to guidelines provided in the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011). The Cochrane Airways Group Trials Search Co-ordina-
tor designed and performed the search process, and two review
authors with expert clinical knowledge independently screened
search results. We are confident that we identified all potentially
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relevant randomised trials. Similarly, two review authors indepen-
dently performed each step in the systematic review process re-
quiring a subjective decision (e.g. extraction of data, assessment of
risk of bias, GRADE assessment) and, if necessary, resolved dis-
agreements by consulting a third review author. A potential sam-
ple bias could result from the selective use of disaggregated data;
however, this approach is a pragmatic necessity. This review has
undergone editorial and peer review to ensure that the opinion of
external experts has been considered. Therefore, we are confident
that our conclusions fairly represent the current evidence base for
this clinical question.
Agreements and disagreements with other
studies or reviews
More than a decade ago, Le Fevre 2002 conducted a systematic
review of randomised controlled trials in adults and children that
compared written action plans versus no plan (five studies) and
peak flow monitoring without a plan versus peak flow monitoring
with a plan (two studies). Heterogeneity of included studies pre-
cluded meta-analysis, and a narrative review of findings suggested
that most studies did not report improved outcomes with addi-
tion of an action plan. However, review authors suggested that all
included studies were of low quality, limiting confidence in the
findings, and stated that evidence available at the time did not
permit firm conclusions. The current review includes more recent
studies, although our finding that many studies are of low quality
and our limited confidence in findings of little evidence of benefit
(or harm) are similar.
Bhogal 2006 reviewed the effect of providing PAAPs for children
specifically and found no studies that compared provision of a
PAAP versus no PAAP. A later paper (Zemek 2008) updated the
search and included one extra study, which did look at the com-
parison of PAAP versus no PAAP. Review authors reported that
this one study (with 68 children) suggested that an action plan
reduced the mean number of acute care visits, symptoms and noc-
turnal awakenings and reduced time lost from school, but again
could offer no firm conclusions on the effectiveness of a PAAP on
the basis of this single study. Individual non-randomised studies
also support benefit for PAAPs. For example, among patients with
moderate to severe asthma, not possessing a written asthma action
plan was associated with increased acute use of healthcare services
(Adams 2009).
PAAPs are often included as part of self-management programmes,
and Powell 2002 examined different aspects of self-management
programmes for adults (over 16 years of age), including PAAPs.
Six studies compared self-adjustment of medications according to
a PAAP versus adjustment by a doctor and found no differences
in outcomes including hospitalisation, emergency department vis-
its, unscheduled doctor visits and incidence of nocturnal asthma;
therefore, study authors concluded that the two approaches were
equally effective. Only one study compared written plans versus
verbal instruction and found no difference in healthcare use or
lung function, but study authors suggested that this findingneeded
further corroboration in future studies. Gibson 2003 reviewed 36
trials comparing self-management education approaches for adults
(over 16 years of age) versus usual care; 18 included a written
PAAP. In general, review authors found that self-management re-
duced hospitalisations, ED visits, unscheduled doctor visits, days
off work or school and incidence of nocturnal asthma, and that
it improved quality of life (but not lung function). In subgroup
analyses of studies implementing optimal self-management edu-
cation (which involved a written plan, self-monitoring and regular
review), many positive outcomes remained (reduced hospitalisa-
tions, ED visits, unscheduled doctor visits and incidence of noc-
turnal asthma). Study evidence led review authors to conclude that
self-management was effective, and in particular that optimal self-
management education should be offered to adults with asthma.
However, it was not possible to discern from this review the con-
tributions of action plans specifically. Furthermore, findings from
this review are now over a decade old.
Tapp 2007 focused on adults who had attended an ED for an
asthma exacerbation and examined whether asthma education (in-
cluding written PAAPs) improved health outcomes. The investi-
gators found that education reduced hospital (re)admission (high-
quality evidence) but did not appear to reduce re-presentation at
an ED (low-quality evidence). Education also led to improved
symptoms but not to improvement in peak flow, quality of life
or days of work/study lost (but these null outcomes involved few
studies and large variation across studies). In addition, the educa-
tion provided revealed considerable heterogeneity across all studies
reviewed, for example, only nine of the 13 included studies pro-
vided a PAAP, and again, the effectiveness of the PAAP specifically
could not be ascertained.
More recently, Peytremann-Bridevaux 2015 evaluated the ef-
fectiveness of chronic disease self-management programmes for
asthma in 20 included studies (12 provided action plans as part
of the programme). In addition to self-management, these pro-
grammes included an organisational component targeting patients
and one targeting professionals, as well as at least two healthcare
professionals involved in the patient’s care. Given the complexity
of these programmes, it was not possible to determine the effect
of action plans alone. Indeed as the review authors note, in some
studies, participants in both intervention and usual care arms had
action plans; in other studies, the proportion of participants using
action plans changed throughout the study; and in other studies,
the proportion of participants with plans was not reported.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Development of a PAAP and structured education for patients
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are endorsed by BTS and NICE guidelines (BTS/SIGN 2016;
NICE 2013). Our findings are based on a small number of stud-
ies of poor quality, so results of this review should be interpreted
with caution. Furthermore, we have identifiedmultiple confound-
ing factors that would make it difficult to demonstrate efficacy
for a single component of a multi-component self-management
strategy (Pinnock 2015; Ring 2011). With consideration of these
caveats, this systematic review, which considered evidence from
randomised controlled trials, did not find additional benefit from
the use of PAAPs, with or without education, across key asthma
outcomes including exacerbation frequency, hospitalisation and
measures of asthma control. Equally, there was no indication from
the included studies of adverse outcomes with the use of PAAPs.
Implications for research
Review conclusions are based on a relatively small number of stud-
ies of poor quality, and interpretation is limited by lack of consis-
tency in terms of design, populations, interventions and outcomes.
Further high-quality research is required to determine whether
PAAPs alone, or in combination with education, have an impact
on important outcomes such as symptom control and indirect
costs such as days lost from work. Future studies should reflect a
broad population demographic, including older adults and peo-
ple from different ethnic groups. The format of PAAPs used in
future research should be consistent with BTS/SIGN guidelines
(BTS/SIGN 2016), that is, they “should include specific advice
about recognising loss of asthma control, assessed by symptoms or
peak flows or both; and actions, summarised as two or three action
points, to take if asthma deteriorates, including seeking emergency
help, starting oral steroids (which may include provision of an
emergency course of steroid tablets), restarting or temporarily in-
creasing (as opposed to just doubling) ICS, as appropriate to clin-
ical severity”. Furthermore, careful consideration should be given
to whether selected outcomes could confound study findings as
the result of overlap with measures instructed by PAAPs.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ayres 1996
Methods Study design: randomised, open-label, parallel-group: 2 groups, self-management plan
(SM) and doctor-managed (DM)
Total duration of study: 24 ± 2 weeks.
Details of any ’run-in’ period: not reported.
Number of centres and locations: hospitals and general practice centres, UK; no further
details
Study setting: primary and secondary care.
Withdrawals: 1 did not receive treatment following randomisation. 32 discontinued
treatment and were withdrawn (22 in SM group, 10 in DM group). Participants were
withdrawn for the following reasons: non-compliance (SM 8; DM 4); asthma deteriora-
tion (SM 3; DM 3); pregnancy/lack of contraception (SM 2); excluded medication (SM
2); adverse events (SM 5; DM 1); and other (SM 2; DM 2)
Date of study: not reported.
Participants Number of participants: 126. Full analysis SM 61, DM 64. Per-protocol analysis SM
21, DM 29
Mean age: in years. Full analysis SM 44 ± 2, DM 47 ± 2. Per-protocol analysis SM 42
± 3, DM 50 ± 3
Age range: not reported.
Gender: full analysis SM M/F 23/38, DM M/F 28/36. Per-protocol analysis SM M/F
7/14, DM M/F 13/16
Severity of condition: nocturnal awakening despite use of inhaled prophylactic therapy
(inhaled corticosteroids 400 to 1600 µg·day-1, sodium cromoglycate or nedocromil
sodium) for a minimum of 3 months
Diagnostic criteria: documented increase (≥ 15%) in FEV1 following inhalation of a
β2-agonist and/or documented diurnal variation in PEF (≥ 15%).
Baseline lung function (% potential normal PEF on prophylaxis): full analysis self-
managed 79%; full analysis doctor-managed 72%
Smoking history: not reported.
Study inclusion criteria: aged 17 years or older, with a documented increase (≥ 15%) in
FEV1 following inhalation of a β2-agonist and/or documented diurnal variation in PEF
(≥ 15%) plus ≥ 1 documented exacerbation of asthma in the previous 6 months that
required contact with a doctor/nurse. Patients had disturbed sleep (which included early
morning awakening due to asthma) on at least 3 nights in the week before enrolment
into the study despite use of inhaled prophylactic therapy (inhaled corticosteroids 400
to 1600 µg·day-1, sodium cromoglycate or nedocromil sodium) for a minimum of 3
months
Study exclusion criteria: use of LABA, anticholinergics, corticosteroids (other than by
the inhaled route) within the past 4 weeks; routine/regular use of a Turbohaler® in
the 6 months before entry; respiratory tract infection at, or within 2 weeks of, entry;
significant disease that could have interfered with the study; pregnancy, lactation or lack
of adequate contraception; and previous participation in the study or participation in
any other clinical study in the 6 months before entry
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Ayres 1996 (Continued)
Interventions Intervention: written guidelines on how to adjust budesonide dose on the basis of
morning PEF measurements (best of 3 attempts before terbutaline use) as a percentage
of their “normal” PEF
Comparison: dose adjusted by investigator at clinic.
Concomitant medications and excluded medications: Participants received budes-
onide (Turbohaler® 200; Astra: 200, 400 or 800 µg BID)
Outcomes Primary outcomes: number of sleep-disturbed nights due to asthma.
Secondary outcomes: lung function (PEF); asthma symptom scores and activity assess-
ments; hospitalisation due to exacerbations;
4 visits to clinic at 6 ± 1 weekly intervals.
Notes Funding for trial: Astra Pharmacuticals Ltd, UK.
Notable conflicts of interest of trial authors: not reported.
Correspondence with trial authors: none.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient details provided.
Allocation concealment (selection bias) Unclear risk Insufficient details provided.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible to blind participants (self-
management of budesonide vs doctor-
managed). Not possible to blind personnel
(but sleep disturbance, daytime symptoms
and activity scores unlikely to be influenced
by lack of blinding)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Self-reported outcomes and lung function
and medication usage likely to be influ-
enced by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk One hundred twenty-six participants were
randomised into the study. One hundred
twenty-five participants received treatment
andwere included in the analysis. Fifty par-
ticipants completed the study without vio-
lating the protocol andwere included in the
per-protocol analysis. Demographic char-
acteristics of participants for both analyses
are presented in Table 1. Thirty-two par-
ticipants discontinued treatment and were
withdrawn from the study - 22 in the SM
group and 10 in the DM group
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Ayres 1996 (Continued)
Selective reporting (reporting bias) Unclear risk Protocol not available.
Other bias Low risk Appears to be free of other sources of bias.
Baldwin 1995
Methods Study design: randomised, parallel-group, open-label.
Total duration of study: approximately 9 months.
Details of any ’run-in’ period: not reported.
Number of centres and location: 1 urban general practice in North Staffordshire, UK.
Study setting: general practice/primary care.
Withdrawals: none.
Date of study: not reported.
Participants Number of participants: 50 (25 in each group).
Mean age: not reported (aged 17 to 39 years: 26 (verbal 11, written 15); aged 40 to 59
years: 16 (verbal 9, written 7); aged 60 to 70 years: 8 (verbal 5, written 3))
Age range: 17 to 74 years.
Gender: M 23, F 37 (verbal M 10, F 15; written M 13, F 12).
Severity of condition: PEF less than 75% of predicted value.
Diagnostic criteria: diagnosis of asthma based on detailed history and presence of PEF
below 75% of predicted value
Baseline lung function: verbal: highest PEF 350 L/min; written: highest PEF 335 L/
min
Smoking history: current smokers: 7 (verbal 4, written 3); ex-smokers: 15 (verbal 6,
written 9); non-smokers: 28 (verbal 15, written 13)
Study inclusion criteria: patients registered with the practice with a diagnosis of asthma
and PEF less than 75% of predicted value
Study exclusion criteria: illiteracy, pregnancy, history of occupational asthma, chronic
lung disease other than asthma and heart disease
Interventions Intervention: written instructions on asthmamanagement in the form of a management
plan, instruction in the use of Mini-Wright® peak flow meters
Comparison: verbal instructions on asthmamanagement, instruction in the use ofMini-
Wright® peak flow meters
Concomitant medications and excluded medications: not reported.
Outcomes Primaryoutcomes: lung functionmeasured on3occasions in clinic at 3-month intervals;
objective assessment of inhaler technique via a 5-point scoring system (based on highest
PEF score, PEF variability score, bronchodilator use, nocturnal symptoms, lifestyle,
additional medication); number of home visits, emergency admissions or attendances at
hospital for exacerbations of asthma (12 months before the study and for subsequent 12
months) noted but not reported; medication recorded at start and finish of the study
period (primary outcome not stated)
Secondary outcomes: Distinction between primary and secondary outcomes was not
made/reported
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Baldwin 1995 (Continued)
Notes Funding for trial: not reported.
Notable conflicts of interest of trial authors: not reported.
Correspondence with trial authors: requested data on number of participants requiring
admission/ED visit, reported by group (verbal or written). Pending response
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants assigned to study groups by
random number generation. No further in-
formation provided
Allocation concealment (selection bias) Unclear risk Insufficient details provided.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding of personnel and participants not
performed (not practical/feasible)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “assessment was made by another doctor,
instructions given and PEF recorded. To
avoid bias, the assessor was unaware of
scores given at successive visits”. However,
doctor would be aware of the group to
which a participant was assigned
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Study does not report drop-outs or num-
ber of participants on whom the data were
based
Selective reporting (reporting bias) Unclear risk Study protocol not available. It would ap-
pear that all intended outcomes have been
reported, apart from the second clinic visit
assessment interval
Other bias Low risk The 2 groups were imbalanced in terms
of the severity of asthma at baseline. This
study was used to test the validity of
the Midland Thoracic Society measure of
morbidity scale (BMJ 1995;310:255). Al-
though this scale features objective mea-
sures such as drug use and peak flow, it also
features subjective measures such as “noc-
turnal symptoms in the week before the
clinic visit (seven items); symptoms affect-
ing lifestyle since the last clinic visit (six
items)”. Participant recall since last clinic
visit, 3months before,may have influenced
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Baldwin 1995 (Continued)
scores, as participants were not asked to
keep diaries. However, this study did not
contribute outcome data to the review
Charrois 2006
Methods Study design: randomised, parallel-group, open-label.
Total duration of study: 6 months.
Details of any ’run-in’ period: no run-in period.
Number of centres and locations: 4 Hinton pharmacies and 1 pharmacy in Edson,
Canada.
Study setting: Pharmacy/community.
Withdrawals: 7 withdrawals; 2 lost to follow-up; 9 incomplete data; 1 protocol violation
Date of study: not reported.
Participants Number of participants: 70.
Mean (SD) age, years: Intervention: 35.7 (10.2); control: 38.7 (10.7).
Age range: not reported.
Gender, n female/male: intervention: 19/17; control: 18/16.
Severity of condition: high risk (see inclusion criteria).
Diagnostic criteria: Canadian National Guidelines.
Baseline lung function: not reported.
Smoking history, % current smoker: intervention: 30.6; control: 29.4.
Study inclusion criteria: self-reported diagnosis of asthma; 17 to 54 years of age and
considered at high risk (ED visit or hospital admission due to asthma in the previous
12 months or use of more than 2 canisters of inhaled beta2-agonist in the previous 6
months, which far exceeds the definition for asthma control as outlined by the Canadian
guidelines)
Study exclusion criteria: patients not responsible for administering their own asthma
medications, unable to understand English, unavailable for 6-month follow-up, did not
provide written informed consent
Interventions Intervention: education on asthma,assessment, optimisation of drug therapy by the
pharmacist and referral to an RT and/or physician as needed. Education component
included instruction on all asthma medications, with focus on the development of a
written action plan (PEF- and symptom-based)
Comparison: The usual care group was given an asthma education booklet and general
advice as needed
Concomitant medications and excluded medications: not reported.
Outcomes Primary outcomes: comparison of the difference between intervention and usual care
groups in terms of change in ACQ scores from baseline to 6 months; score 0 to 6 (0
indicating the best level of control, 6 indicating the poorest level of control); improvement
of 0.5 or more points considered clinically significant
Secondary outcomes: comparisons between intervention and usual care groups in terms
of numbers of EDvisits and hospital admissions, use of inhaled corticosteroid (at baseline
and at 6 months), number of courses of oral steroid, FEV1 (at baseline and at 2 and 6
months).
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Charrois 2006 (Continued)
Notes Funding for trial: Financial support was provided by Canadian Institutes of Health
Research, Institute ofHealth Economics,UniversityHospital Foundation andASTHMA
Study (Alberta Strategy to Help Manage Asthma)
Notable conflicts of interest of trial authors: not reported.
Correspondence with trial authors: not required.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation accomplished
through an internet randomisation service
(EPICORE)
Allocation concealment (selection bias) Low risk Randomisation accomplished
through an internet randomisation service
(EPICORE)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No participant blinding evident; pharma-
cists providing PAAPs not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear whether respiratory technicians,
who performed the assessments, were
blinded to the group
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants except 1 (protocol devia-
tion) in the intervention group included in
the analyses
Selective reporting (reporting bias) Low risk All outcomes listed in the protocol re-
ported.
Other bias High risk Study authors state that pharmacist com-
pliance with the intervention was poor.
Only 3/4 in the intervention group re-
ceived a WAAP. Less than half of partici-
pants received education about WAAP at
each pharmacy visit. Education provided
for intervention and comparator groups
may have been subtly different
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Cowie 1997
Methods Study design: randomised, parallel-group (3), single-blind (assessor blinded)
Total duration of study: 6 months.
Details of any ’run-in’ period: no run-in period.
Number of centres and location: Calgary, Canada.
Study setting: secondary care.
Withdrawals: 11 withdrew or were lost to follow-up.
Date of study: not reported.
Participants Number of participants: 151 (139 completed the study).
Mean (SD) age, years: peak flow plan: 39.1 (14.41); symptom plan: 36.8 (16.50); no
plan: 36.4 (12.76)
Age range: not reported.
Gender, n M/F: peak flow plan: 29/17; symptom plan: 25/20; no plan: 29/19.
Severity of condition: patients who had received urgent treatment for asthma in the
previous 12 months; moderate to severe
Diagnostic criteria: not reported.
Baseline lung function - % predicted FEV1 (SD): peak flow plan: 82 (20.5); symptom
plan: 79 (18); no plan: 78 (21.3)
Smoking history: not reported.
Study inclusion criteria:history of receiving urgent treatment for asthma in the previous
12 months
Study exclusion criteria: patients with written asthma plans.
Interventions Intervention: symptom-based action plan or peak flow-based action plan.
Comparison: no action plan.
Concomitant medications and excluded medications: not reported.
Outcomes Primary outcomes: attendance for urgent treatment of asthma.
Secondary outcomes: asthma control.
Notes Funding for trial: not reported.
Notable conflicts of interest of trial authors: not reported.
Correspondence with trial authors: not required.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation achieved by use of 3 lists
of random numbers, combined in database
and indexed in ascending order
Allocation concealment (selection bias) Low risk Allocation concealed using 150 sequen-
tially numbered sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible to blind participants and per-
sonnel owing to the nature of the interven-
tion
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Cowie 1997 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Baseline interview, spirometry and educa-
tion performed before consent and ran-
domisation. Research assistants who per-
formed telephone interview 6 months af-
ter enrolment blinded to participant allo-
cation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 11 of 150 participants lost to follow-
up and loss to follow-up equally distributed
across groups
Selective reporting (reporting bias) High risk Primary outcome - comparison between
groups regarding degree of asthma con-
trol and attendance for urgent treatment
of asthma. Latter reported. However, data
regarding asthma control not presented:
night-time waking, reliever use, self-rating
of asthma severity, daily dose of IHC or
prednisolone course
Other bias Low risk None identified.
Griffiths 2004
Methods Study design: cluster randomised controlled trial, open-label (analysis blinded)
Total duration of study: 1 year.
Details of any ’run-in’ period: no run-in period.
Number of centres and locations: 44 general practices in 2 boroughs in east London.
Study setting: primary care.
Withdrawals: primary outcome data available for 319/324 (98%) participants
Date of study: not reported.
Participants Number of participants: 324.
Mean (SD) age: intervention: 22.9 (17.4); control: 22.2 (18.1).
Age range: aged 4 to 60 years.
Gender, n male (%): intervention: 85 (49); control: 76 (51).
Severity of condition: acute asthma requiring attendance at hospital or general practi-
tioner out of hours service
Diagnostic criteria: not reported.
Baseline lung function: not reported.
Smoking history (in patients > 16 years only), n smoker (%): intervention: 26 (31);
control: 24 (35).
Study inclusion criteria: patients who attended hospital or GP practice for acute asthma
and with sufficient understanding to follow a self-management plan
Study exclusion criteria: not reported.
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Griffiths 2004 (Continued)
Interventions Intervention: participant review in a nurse-led clinic and liaison with general practi-
tioners and practice nurses comprising educational outreach, promotion of guidelines
for high-risk asthma and ongoing clinical support; participants with sufficient under-
standing provided with a peak flow meter, a supply of rescue oral corticosteroids for
future use and a written plan produced by theNational Asthma Campaign with standard
thresholds for peak flow and symptoms
Comparison: Control practices received a visit promoting standard asthma guidelines;
control participants were checked for inhaler technique
Concomitant medications and excluded medications: not reported.
Outcomes Primary outcomes: percentage of participants receiving unscheduled care for acute
asthma over 1 year
Secondary outcomes: rates of attendance for unscheduled care and review, self-man-
agement behaviour, quality of life, assessed by generic (EQ-5D) and respiratory-specific
(AQ20
and north of England) scales.
Notes Study authors contacted for disaggregated data. Study author (Dr. Griffiths) replied just
before submission of the review to say that the data could potentially become available
pending a data sharing agreement thatwas being set up.Data to be included in subsequent
update of review if available owing to lack of time remaining on the grant
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Forty-four GP practices randomised via a
minimisation programme - stratifying by
partnership size and other criteria
Allocation concealment (selection bias) Unclear risk Insufficient details provided.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Cluster randomised trial. Blinding not fea-
sible.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Researchers blinded to randomisation
status of each practice extracted data
fromwritten and computerised participant
records from both primary and secondary
care. A research officer removed any special-
ist nurse letters tomaintain blinding. Com-
pleteness and accuracy of extraction was
validated by another blinded researcher,
who checked 10 sets of records, using ran-
dom numbers
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Griffiths 2004 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Researchers were able to extract health
record data for most participants recruited
(98%)
Selective reporting (reporting bias) Unclear risk Abstract only. Protocol not available.
Other bias Unclear risk Control group included a higher percent-
age of participants who were fluent in En-
glish (89% vs 81%). Although randomi-
sation resulted in equal groups at a prac-
tice level, this resulted in more participants
recruited from intervention practices than
from control (n = 175 vs n = 149)
Hoskins 1996
Methods Study design: cluster randomised controlled trial.
Total duration of study: 6 months.
Details of any ’run-in’ period: no run-in period.
Number of centres and locations: 290 GP practices in the UK that participated in the
second national audit on asthma attacks (1991-1992)
Study setting: primary care.
Withdrawals: NA.
Date of study: 1993.
Participants Number of participants: 290 GP practices randomised; data from 906 participants
useable
Mean age: not reported.
Age range: not reported.
Gender: not reported.
Severity of condition: exacerbation in previous 3 months.
Diagnostic criteria: not reported.
Baseline lung function: not reported.
Smoking history: not reported.
Study inclusion criteria: asthma exacerbation in previous 3 months.
Study exclusion criteria: not reported.
Interventions Intervention: 3-step self-management plan consistent with BTS guidelines.
Comparison: usual care; no plan.
Concomitant medications and excluded medications: not reported.
Outcomes Outcomes: exacerbation resulting in hospital admission; exacerbation resulting in emer-
gency department visit; patient-initiated GP consultation for asthma; GP asthma review
consultation; course of oral steroids or use of emergency nebulised bronchodilator for
asthma (each assessed at 6 months)
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Hoskins 1996 (Continued)
Notes Funding for trial: an educational grant from Allen and Hanburys Limited.
Notable conflicts of interest of trial authors: not reported.
Correspondence with trial authors: not required.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk General practitioners in the UK who had
participated in the second national audit
of asthma attacks in 1992-1993 were ran-
domised (1:1) into intervention and con-
trol groups through a predetermined ran-
domnumbers sequence; however, study au-
thors do not say how random number se-
quence was generated
Allocation concealment (selection bias) Unclear risk Insufficient details provided.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk GP not blinded to which group his/her
patients were allocated; participants knew
which group they were in (if made aware
of the study)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk General practitioners who participated in
this study were a self-selected group with
an interest in audit. Participants were likely
to have shown enthusiasm and commit-
ment and encouraged their patients to fol-
low plans in an attempt to reduce morbid-
ity. Six months later, both groups of doc-
tors were invited to complete a morbid-
ity questionnaire for each patient recruited.
GP completed questionnaire on outcomes
Incomplete outcome data (attrition bias)
All outcomes
High risk Data were reported for only 51% of GPs in
the intervention group vs 83% of those in
the comparator group
Selective reporting (reporting bias) Unclear risk Study protocol not available. All outcomes
listed in Methods section reported in Re-
sults section
Other bias High risk Despite randomisation, measures of pa-
tient morbidity in the intervention group
before the issue of self-management plans
were much higher than in the control
group. A plausible explanation is that gen-
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Hoskins 1996 (Continued)
eral practitioners in the intervention group
elected to issue plans to patients with un-
controlled asthma, rather than to all pa-
tients whowere eligible to receive them.No
data on number of patients that GPs en-
rolled into the study, only data on number
of patients for whom GPs returned ques-
tionnaires and howmany of these were use-
able
Jones 1995
Methods Study design: randomised, parallel-group (2), open-label (analysis blinded)
Total duration of study: 6 months.
Details of any ’run-in’ period: no run-in period.
Number of centres and locations: 25 general practices in the Wessex region (UK).
Study setting: primary care.
Withdrawals: 55 participants failed to complete the study.
Date of study: August 1990 to February 1992.
Participants Number of participants: 127 randomised; 72 completed the study.
Mean (SD) age, years: intervention: 30.4 (11.5); control: 28.6 (7.0).
Age range: not reported.
Gender, n M/F: intervention: 14/19; control: 13/26.
Severity of condition: not stated.
Diagnostic criteria: not stated.
Baseline lung function - % predicted FEV1 (SD): intervention: 85.1 (20.8); control:
80.2 (19.9).
Smoking history, % non/passive/smoker: intervention: 55/15/30; control: 36/26/38.
Study inclusion criteria: aged 15 to 40 years; use of metered dose steroid inhaler (dose
< 1001 micrograms per day, or dry powder equivalent)
Study exclusion criteria: patients on regular oral steroids; patients already possessing
and regularly using a peak flow meter
Interventions Intervention: written self-management plan, peak flow-based.
Comparison: usual care.
Concomitant medications and excluded medications: not reported.
Outcomes Primary outcomes: lung function, quality of life (at 6 months vs baseline).
Secondary outcomes: days lost fromwork or school (comparing 4 weeks before baseline
and visits at 6 months); interference with daily life; symptom scores; bronchodilator use
Notes Funding for trial: The study was funded by a grant from Allen and Hanburys.
Notable conflicts of interest of trial authors: not reported.
Correspondence with trial authors: not required.
Risk of bias
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Jones 1995 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation to a self-management
group or a planned visit group stratified by
centre in blocks of 6. Insufficient details
Allocation concealment (selection bias) Unclear risk No details of allocation sequence conceal-
ment given.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible to blind participants or prac-
tice staff.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information on who extracted
data on medical resource use and prescrib-
ing data from medical records. However,
personnel undertaking analysis blinded to
group allocation
Incomplete outcome data (attrition bias)
All outcomes
High risk Mean group symptom scores not presented
for each of the review intervals. No patient
flow diagram presented - 127 recruited, 72
completed. 30% dropped out but not clear
howmanywere lost to each groupnor losses
at each review point. Quality of life data
not clearly presented
Selective reporting (reporting bias) High risk Mean symptom scores at measurement in-
tervals not presented. Uncertain what the
“Time to first symptom” equates to. Very
little reference made to quality of life data
Other bias Low risk Appears to be free of other bias.
Klein 1998
Methods Study design: randomised, parallel-group (2), open-label.
Total duration of study: 2 years.
Details of any ’run-in’ period: no run-in period.
Number of centres and location: Department of Pulmonary Medicine of a teaching
hospital (1100 beds) in Enschede, the Netherlands
Study setting: tertiary care.
Withdrawals: year 1: 6 lost to follow-up, 1 death; year 2: 1 death.
Date of study: August 1995 to April 1996.
Participants Number of participants: 245 randomised.
Mean (SD) age, years: intervention: 43.5 (11.7); control: 45.2 (12.0).
Age range: not reported.
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Klein 1998 (Continued)
Gender, n M/F: intervention: 51/72; control: 60/62.
Severity of condition: stable asthma with continuous use of inhaled steroids (> 200
micrograms per day metered dose inhaler)
Diagnostic criteria: European Respiratory Society.
Baseline lung function, % predicted FEV1 (SD): intervention: 76 (20); control: 76.9
(20.1).
Smoking history, % non/ex/current: intervention: 54.4/35.8/9.8; control: 51.7/35.2/
13.1.
Study inclusion criteria: between the ages of 18 and 65;continuous use of inhaled
steroids (≥ 200mg/d bymetered dose inhaler (MDI) or400mg/d by dry powder inhaler)
for ≥ 3 months; in a stable phase of disease during last 6 weeks, defined as no use of
short courses of oral steroids or no increase in maintenance dose of oral steroids; ability
to speak and read the Dutch language
Study exclusion criteria: not stated.
Interventions Intervention: asthmanurse-led educationpluswritten self-management plan (peakflow-
and symptom-based)
Comparison: asthma nurse-led education, no plan.
Concomitant medications and excluded medications: not reported.
Outcomes Primary outcomes: pulmonary function at baseline and at 4, 8, 12, 18 and 24 months
after entry (pre-bronchodilator FEV1 (%predicted) and from2-week diariesmeanmorn-
ing pre-bronchodilator PEF and mean diurnal PEF variability together with PC20 his-
tamine at baseline and at 12 months); asthma morbidity parameters (frequency of ex-
acerbations at baseline and at 4, 8, 12, 18 and 24 months; use of healthcare facilities
during the year before and the first and second years after the intervention (numbers of
outpatient visits, hospitalisations and hospital days)
Notes Funding for trial: Netherlands Asthma Foundation (Grant 94-52), GlaxoWellcome,
the “StichtingAstmabestrijding” and Amicon Health Care Insurance Fund
Notable conflicts of interest of trial authors: not reported.
Correspondence with trial authors: not required.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information provided.
Allocation concealment (selection bias) Low risk Remaining 245 participants randomised
into a self-treatment group (group S) and a
control group (group C) by a closed enve-
lope method
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not possible and outcomes possi-
bly influenced by lack of blinding
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Klein 1998 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information provided to make
a judgement.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Few drop-outs baseline to 12 months,
greater number of drop-outs 12 months
to 24 months. However, 12-month data
can be examined separately from24-month
data. Study extended from original 1-year
plan to 2 years after commencing. High
drop-out rates going into year 2 - mainly
younger people. Potential to skew data
Selective reporting (reporting bias) Low risk Appears that all prespecified outcomes in
Methods section have been reported in
Results section. Some outcomes (e.g. per-
ceived control of asthma, self-confidence)
reported only for the 1-year interval - not
at 2 years
Other bias Low risk Appears to be free of other sources of bias.
McArdle 1997
Methods Study design: randomised, parallel-group (2), open-label.
Total duration of study: 6 months.
Details of any ’run-in’ period: no run-in period.
Number of centres and location: single outpatient clinic of large inner city hospital,
Australia
Study setting: secondary care.
Withdrawals: data reported for 41/45 randomised participants; reasons for loss not
reported
Date of study: not reported.
Participants Number of participants: 45 participants randomised.
Mean age: not reported (abstract only).
Age range: not reported (abstract only).
Gender: not reported (abstract only).
Severity of condition: not reported (abstract only).
Diagnostic criteria: not reported (abstract only).
Baseline lung function: not reported (abstract only).
Smoking history: not reported (abstract only).
Study inclusion criteria: patients with a diagnosis of asthma .
Study exclusion criteria: not reported (abstract only).
Interventions Intervention: generalised asthma education plus written asthma action plan (peak flow-
based)
Comparison: generalised asthma education only.
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Concomitant medications and excluded medications: not stated (abstract only).
Outcomes Primary outcomes: adherence to plan.
Secondary outcomes: symptom score.
Notes Funding for trial: not reported (abstract only).
Notable conflicts of interest of trial authors: not reported (abstract only).
Correspondence with trial authors: trial authors contacted for more detailed data not
presented in the abstract. Trial authors agreed to search for data on return to office; no
further contact
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient details provided.
Allocation concealment (selection bias) Unclear risk Insufficient details provided.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding would not be feasible.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient details provided.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data reported for 91% of participants.
Selective reporting (reporting bias) Unclear risk Study protocol not available.
Other bias Low risk None identified.
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Methods Study design: prospective, randomised, parallel-group (2), open-label trial
Total duration of study: 12 months (additional follow-up at 5 years).
Details of any ’run-in’ period: 2 weeks; ability of participants in the self-management
group to measure peak expiratory values evaluated
Number of centres and locations: outpatient departments of 2 tertiary reference clinics
in Serbia
Study setting: tertiary care (outpatient).
Withdrawals: 6 participants dropped out (3 from each group).
Date of study: Patients entered the trial at staggered intervals from September 1999 to
September 2000
Participants Number of participants: 80 randomised participants.
Mean (SD) age, years: intervention: 49.1 (14.4); control: 44.9 (11.7).
Age range: not reported.
Gender, n M/F: intervention: 17/20; control: 18/19.
Severity of condition, % mild/moderate/severe: intervention: 51/35/14; control: 54/
35/16.
Diagnostic criteria: “The diagnosis was confirmed and treatment prescribed according
to the national and international asthma guidelines”
Baseline lung function - mean (SD) FEV1, L: intervention: 2.47 (0.78); control: 2.48
(0.55).
Smoking history, % never/ex/current: intervention: 75/25/0; control: 70/30/0.
Study inclusion criteria: age between 18 and 60 years; continuous use of inhaled steroids
for at least last 1 year; stable phase of disease during last 3 months
Study exclusion criteria: smoking history of 15 or more pack-years; other diseases that
could influence bronchial symptoms and/or lung function
Interventions Intervention: individual written action plan based on peak flow measurements
Comparison: usual care; no peak flowmeter. Participants were instructed to take reliever
medication if their asthma symptoms deteriorated and to seek advice from their primary
care physician regarding controller medication
Concomitant medications and excluded medications: not reported.
Outcomes Outcomes: lung function; number of asthma exacerbations; number of hospital admis-
sions; number of unscheduled visits (including visits to emergency department, general
practitioner or pulmonologist); treatment requirements during asthma exacerbations
(courses of doubling dose of inhaled corticosteroids, use of oral prednisolone and antibi-
otics); days off work because of asthma exacerbations and asthma symptoms
Notes Funding for trial: not reported.
Notable conflicts of interest of trial authors: not reported.
Correspondence with trial authors: none required.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient details provided.
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Allocation concealment (selection bias) Unclear risk Insufficient details provided.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unlikely that blinding possible.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outpatient visits scheduled every 6months
- clinical state and course of treatment eval-
uated by a physician as per routine clinical
practice. Insufficient information provided
to make a judgement
Incomplete outcome data (attrition bias)
All outcomes
Low risk 40 participants randomised to each group.
Attrition of 3 participants per group by 1-
year interval (37 vs 37)
Selective reporting (reporting bias) Unclear risk Study protocol not available.
Other bias Low risk None identified.
Nokela 2010
Methods Study design: cluster randomised trial.
Total duration of study: 14 weeks.
Details of any ’run-in’ period: none.
Number of centres and locations: 19 primary healthcare centres in the Stockholm area.
Study setting: primary health care.
Withdrawals: 11 participants in the control group and 10 in the intervention group
were lost to follow-up for unknown reasons. One participant in the intervention group
did not meet the age inclusion criteria and was therefore excluded. Three controls and
2 participants in the intervention group completed the second visit much later than
planned in the protocol (20 to 32 weeks overdue) and were therefore excluded. Thus, 64
participants in the intervention group and 77 in the control group completed the study
Date of study: From October 2003 until December 2004.
Participants Number of participants: 141.
Mean age (range), years: intervention: 48 (19 to 87); control: 52.5 (18 to 79).
Age range: 18 to 87 years.
Gender, n F/M: 98/43.
Severity of condition: not reported.
Diagnostic criteria: ’asthma diagnosis’.
Baseline lung function - mean (min, max) % predicted FEV1, L: intervention: 89
(33, 127); control:82.6 (5, 118).
Smoking history - current/ex/never, %: intervention: 14/45/41; control: 18/40.3/40.
3 (1.3% missing data)
Study inclusion criteria: Centres were instructed to consecutively invite all eligible
patients with an asthma diagnosis who sought medical attention (for any condition) to
participate
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Study exclusion criteria: age < 18 years; poor understanding of written Swedish; ma-
lignant disease; severe psychiatric disease and dementia
Interventions Intervention:provision of additional structuredwritten and oral information (symptom-
based plan), follow-up using an asthma diary
Comparison: according to local treatment routine.
Concomitant medications and excluded medications: not reported.
Outcomes Primary outcomes: change in score on the asthma control questionnaire (ACQ) between
the 2 visits in the study. (Minimum important difference ~0.5.)
Secondary outcomes: lung function measurements (FEV1 or PEF), number of self-
reported emergency visits caused by asthma, number of participants with additional/
unanswered questions about their asthma or its management, prescribed changes in drug
treatment, patient-perceived benefit of asthmamedications, costs of asthmamedications,
changes in disease-specific quality of life. Disease-specific quality of life was measured
using the validated Swedish version of the Mini Asthma Quality of Life Questionnaire
(Mini-AQLQ; MCID 0.5), which yields a total score between 1 and 7, where 7 is the
best and 1 is very poor
Notes Funding for trial: Studywas supported and funded by drug and therapeutics committees
in Stockholm and Sörmland, the Stockholm County Council, the Vårdal Foundation
and the Karolinska Institutet
Notable conflicts of interest of trial authors: none reported.
Correspondence with trial authors: not required.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisationwas performedwith a com-
puter programme that generated random
numbers
Allocation concealment (selection bias) Unclear risk Insufficient details provided.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not possible owing to the nature
of the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Assessors aware of allocation throughout.
Incomplete outcome data (attrition bias)
All outcomes
High risk > 85% follow-up. 11 control, 10 interven-
tion participants lost to follow-up - rea-
sons unknown. Lung function reported in
records for 100% of Intervention partici-
pants (64) and only 91% of control par-
ticipants (77). Also, study authors reported
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mean (SD) point change in outcome mea-
sure between first and second visits - actual
data not presented
Selective reporting (reporting bias) Unclear risk Study protocol not available.
Other bias Unclear risk More smokers in control group (14 vs 9).
Sangha 2004
Methods Study design: randomised, parallel-group (2), open-label.
Total duration of study: 6 months.
Details of any ’run-in’ period: not reported (abstract only).
Number of centres and locations: not reported (abstract only).
Study setting: not reported (abstract only).
Withdrawals: not reported (abstract only).
Date of study: not reported (abstract only).
Participants Number of participants: 100.
Mean age: not reported (abstract only).
Age range: not reported (abstract only).
Gender: not reported (abstract only).
Severity of condition: not reported (abstract only).
Diagnostic criteria: not reported (abstract only).
Baseline lung function: not reported (abstract only).
Smoking history: not reported (abstract only).
Study inclusion criteria: diagnosis of bronchial asthma.
Study exclusion criteria: not reported (abstract only).
Interventions Intervention: education plus peak flow-based written action plan.
Comparison: education.
Concomitant medications and excluded medications: not reported (abstract only).
Outcomes Primary outcomes: lung function parameters at 6 months.
Secondary outcomes: ’morbidity data’.
Notes Funding for trial: not reported (abstract only).
Notable conflicts of interest of trial authors: not reported (abstract only).
Correspondence with trial authors: study authors contacted for further data/informa-
tion. No response at time of submission
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient details provided.
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Allocation concealment (selection bias) Unclear risk Insufficient details provided.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not feasible.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient details provided.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient details provided.
Selective reporting (reporting bias) Unclear risk Protocol not available.
Other bias Low risk None identified (abstract only).
Sheares 2015
Methods Study design: randomised, parallel-group (2), open-label.
Total duration of study: 12 months.
Details of any ’run-in’ period: no run-in period.
Number of centres and locations: 7 pulmonary and allergy practices at 4 urban medical
centres
Study setting: secondary care.
Withdrawals: 7 withdrawals; 10 relocations; 67 lost-to follow-up.
Dates of study: 2006-2009.
Participants Number of participants: 407 participants randomised. 135 adults (33%) and 272
children (67%)
Mean age: not reported.
Age range: not reported.
Gender, n female (%): intervention: 188 (92); control: 175 (86).
Severity of condition: persistent asthma as defined by NAEPP guidelines.
Diagnostic criteria: NAEPP guidelines.
Baseline lung function: not reported.
Smoking history: not reported.
Study inclusion criteria: children and adults aged 5 to80 yearswith a physician diagnosis
of persistent asthma (as defined by NAEPP guidelines)
Study exclusion criteria: diagnosis of a comorbid condition affecting lung health.
Interventions Intervention: written asthma action plan.
Comparison: usual care (no written asthma action plans).
Concomitant medications and excluded medications: not reported.
Outcomes Primary outcomes: asthma symptom frequency, emergency visits, asthma quality of life
(mini-AQLQ score); each at 12 months
Secondary outcomes: participant use of WAAP.
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Notes Funding for trial: supported by the NIH/NHLBI (grant R01HL73955) and the Na-
tional Center for Advancing Translational Sciences, NIH (UL1 TR000040), formerly
the National Center for Research Resources (UL1 RR024156)
Notable conflicts of interest of trial authors: none.
Correspondence with trial authors: trial authors contacted with request for mean age
of cohort. No response at time of submission
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random number se-
quence was used for randomisation. “we
used a randomised block, mixed-effects
factorial design”...“Blocks were of variable
sizes to eliminate predictability”
Allocation concealment (selection bias) Low risk Allocation was concealed in sealed num-
bered envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Double-blinding was not possible. How-
ever, a randomised block designwith physi-
cian as a random factor was used to min-
imise variability due to physician. “The in-
tervention group had a blank WAAP form
inserted into their charts and the control
group had no WAAP form, but a sticker
was applied to the outside of the chart to
remind physicians to provide their usual in-
structions without giving any written ma-
terials other than prescriptions”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information provided to make
a judgement. Presumably, research staff in-
terviewed participant following physician
appointment. Unclear whether staff were
blinded to participant group allocation.
“After the initial visit, participants were in-
terviewed via telephone by staff from the
New England Research Institute (Water-
town, MA) every 3 months during the
12-month follow-up period”. Presumed re-
search institute staff blinded to group allo-
cation but study authors do not state this
Incomplete outcome data (attrition bias)
All outcomes
High risk No one was excluded from the analysis
other than for reason of missing data. A rel-
atively high percentage of randomised par-
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Sheares 2015 (Continued)
ticipants were excluded from analyses for
missing data; inverse proportions of adults/
children were recruited to intervention and
control groups. More children in the In-
tervention group. More participants lost to
follow-up in the intervention group (24%)
compared with the control group (18%)
Selective reporting (reporting bias) Low risk Comparison with NCT website demon-
strates that all comparisons were reported
Other bias Unclear risk Study included both adults and children, so
we need to seek disaggregated data. More
children in the intervention group
Thoonen 2001
Methods Study design: cluster randomised controlled trial.
Total duration of study: 2 years.
Details of any ’run-in’ period: none.
Number of centres and locations: 19 general practices were recruited from 2 pools; the
first were in and around the city of Eindhoven, and the second included practices from
our department’s academic research network; Netherlands
Study setting: primary care.
Withdrawals: 43.
Date of study: not reported.
Participants Number of participants: 214.
Mean (SD) age, years: intervention: 39.6 (11.2); control: 39.3 (12.0).
Age range: not reported.
Gender, n M/F: intervention: 34/64; control: 40/56.
Severity of condition: FEV1 > 40% predicted and > 55% predicted 15 minutes after
salbutamol
Diagnostic criteria: not reported.
Baseline lung function - mean (SD) % predicted FEV1 pre-BD, L: intervention: 84.
0 (13.1); control: 86.9 (14.2).
Smoking history, % never/former/current: intervention: 46/32/22; control: 56/22/
22.
Study inclusion criteria: treated for asthma by GP; age 16 to 60 years; FEV1 > 40%
of predicted value and > 55% of predicted value 15 minutes after inhalation of 800
µg salbutamol or 6 weeks after inhalation of 800 µg budesonide twice daily; FEV1
reversibility (after bronchodilation with 800 µg salbutamol metered dose inhaler or 8
weeks treatment with 800 µg budesonide twice daily) of at least 10% of predicted value
or PC20 histamine of 8 mg/mL
Study exclusion criteria: smoking history of 15 or more pack-years; serious diseases
other than asthma with low survival rates; exacerbations during the month before the
start of the study; other diseases that influence bronchial symptoms and/or lung function
such as heart failure, sarcoidosis; inability to inhale medication correctly or to measure
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and record peak flow adequately and unlikely that this can be taught
Interventions Intervention: written personalised asthma action plan.
Comparison: usual care according to national guidelines.
Concomitant medications and excluded medications: not reported.
Outcomes Primary outcomes: asthma control, asthma-specific quality of life, lost activity days
Secondary outcomes: number of puffs of budesonide, number of dose equivalents of
short-acting bronchodilators, number of short courses of oral prednisolone and antibi-
otics, number of GP-diagnosed exacerbations
Notes Funding for trial: This research project has been made possible by research grants
fromThe NetherlandsOrganization for Scientific Research (NWO) and ASTRAZeneca
Pharmaceutica BV
Notable conflicts of interest of trial authors: reported as ’none’.
Correspondence with trial authors: not required.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information provided.
Allocation concealment (selection bias) Unclear risk Insufficient information provided.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention
and GP practice rather than participant
randomisation, it is not possible to blind
personnel and participants
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “Assessors were not blinded to study group
allocation”.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 104 usual care (UC) and 110 self-manage-
ment (SM) recruited - 95 UC and 98 ITT
analyses. 18 participants did not complete
UC arm, 25 did not complete SM arm
Selective reporting (reporting bias) Unclear risk Protocol not available. All defined out-
comes appear to have been reported
Other bias High risk Study authors noted that participants who
received PAAPs were provided with an oral
course of prednisolone, and that the pre-
scription may have been incorrectly inter-
preted as evidence of use of prednisolone
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during an exacerbation
Wang 2004
Methods Study design: randomised, parallel-group (2), open-label.
Total duration of study: 12 months.
Details of any ’run-in’ period: none.
Number of centres and location: Queen Mary Hospital, Hong Kong.
Study setting: tertiary care.
Withdrawals: 13% lost to follow-up.
Date of study: not reported (abstract only).
Participants Number of participants: 76.
Mean age: not reported (abstract only).
Age range: not reported (abstract only).
Gender: not reported (abstract only).
Severity of condition: “acute asthma”.
Diagnostic criteria: not reported (abstract only).
Baseline lung function: not reported (abstract only).
Smoking history: not reported (abstract only).
Study inclusion criteria: acute asthma.
Study exclusion criteria: not reported (abstract only).
Interventions Intervention: asthma self-management programme with a written self-action plan and
usual care
Comparison: usual care only.
Concomitant medications and excluded medications: not reported (abstract only).
Outcomes Outcomes: ratio of asthma-related hospitalisation, A&E visits, visits to general practi-
tioners, days off work, asthma symptoms, use of medications, lung function; all out-
comes measured at 12 months
Notes Funding for trial: not reported (abstract only).
Notable conflicts of interest of trial authors: not reported (abstract only).
Correspondence with study authors: study authors contacted via email with request
for published data or associated peer-reviewed paper. No response at time of submission
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient details provided.
Allocation concealment (selection bias) Unclear risk Insufficient details provided.
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not feasible.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient details provided.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient details provided.
Selective reporting (reporting bias) Unclear risk Protocol not available.
Other bias Low risk None identified (note abstract only).
Abbreviations: ACQ, Asthma Control Questionnaire; A&E, accident and emergency; AQ20, Airways Questionnaire 20; AQLQ,
Asthma Quality of Life Questionnaire; BTS, British Thoracic Society; DM, doctor-managed; ED, emergency department; EQ-5D,
Euro quality of life five dimensions questionnaire; F, female; FEV1, forced expiratory volume in one second; GP, general practitioner;
ITT, intention-to-treat; LABA, long-acting beta-agonist; M,male;MCID, minimum clinically important difference;MDI, metered-
dose inhaler; Mini-AQLQ, Mini Asthma Quality of Life Questionnaire; NCT, national clinical trial; NHLBI, National Heart, Lung
and Blood Institute; NIH, National Institutes of Health; NAEPP, National Asthma Education and Prevention Program; PAAP,
personalised asthma action plan; PC20, provocation concentration causing a 20% fall in FEV1; PEF, peak expiratory flow; RT,
respiratory technician; SD, standard deviation; SM, self-managed; UC, usual care; WAAP, written asthma action plan.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Adams 2001 Wrong comparator: Study compared peak-flow- vs symptom-based plans; no control group that received no
PAAP
Araújo 2012 Wrong comparator: Participants were randomly assigned to a sequence of Web-based and paper-based diary
and action plan; no control group that received no PAAP
Arguel 2013 Wrong intervention: evaluation of a Web-based personally controlled health management system (PCHMS)
called Healthy.me
Bailey 1990 Wrong intervention: evaluation of a workbook with 1-to-1 counselling and adherence-promoting strategies
Bailey 1999 Wrong intervention: Self-management plans did not appear to include a written action plan
Behera 2006 Wrong comparator: self-care manual, which appeared to involve an educational component (interviews), vs
no manual and no education. Pilot study for Behera 2008.
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Behera 2008 Wrong comparator: self-care manual, which appeared to involve an educational component (interviews), vs
no manual and no education. Pilot study was Behera 2006.
Berg 1996 Wrong intervention: 6-week self-management programme. No specific mention of written asthma plan
Boath 1998 Wrong comparator: peak-flow-based plan vs symptom-based plan; no control group that did not receive any
plan
Breysse 2011 Wrong participant population: ’asthmatic children’.
Buist 2001 Wrong intervention: compares different shared decision-making models
Calhoun 2012 Wrong intervention: Participants in the intervention groups did not appear to receive a personalised written
action plan
Chenu 2000 Wrong comparator: education plus PAAP vs no education and no PAAP
Clark 2005 Wrong intervention: a multiple-component behavioural education programme delivered by a nurse health
educator through telephone counselling
Cleland 2004 Wrong intervention: an interactive seminar delivered at practice level
Couturaud 2002 Wrong comparator: education plus PAAP vs no education and no PAAP
Côté 2001 Wrong comparator: limited education plus PAAP vs structured education plus PAAP vs ’usual care’ (no
PAAP plus no education)
Espinosa 1998 Wrong intervention: ’personal education for one year’.
Fernandes 2011 Wrong intervention: education on inhaler technique by trained respiratory technician
Fonseca 2006 Wrong study design: participant diary vs no participant diary
Ford 1996 Wrong intervention: education vs no education; self-management group does not specify use of PAAP. Pilot
study for Ford 1997.
Ford 1997 Wrong intervention: education vs no education; self-management group does not specify use of PAAP. Piloted
in Ford 1996.
Gaga 2004 Wrong comparator: Usual care comprised specialist-directed adjustments to therapy
Gallefoss 2001 Wrong comparator: structured education plus PAAP vs no PAAP and no education
Goeman 2013 Wrong intervention: No PAAP was issued (the intervention included advice to discuss obtaining a PAAP
from physician)
GRASSIC 1994 Wrong comparator: self-management education plus PAAP vs no PAAP and no self-management education
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Haniotou 2012 Wrong comparator: PAAPplus education/training around breathing technique vs no PAAP and no education
Ignacio 1995 Wrong comparator: Control group received PAAP.
Janson 2009 Wrong comparator: education plus PAAP vs no education and no PAAP
Kelso 1996 Wrong study design: non-randomised.
Kemple 2002a Wrong study design: Randomisation occurred after group allocation
Kim 2016 Wrong intervention: Intervention includes possibility of investigators directly intervening as they monitored
data entered by participants into the mobile-based plan
Kokubu 2000 Wrong comparator: Both groups received a PAAP.
Kotses 1996 Wrong study design: appears to be pseudo-randomised (participants randomised but with the restriction
that groups were balanced for numbers)
Lahdensuo 1994 Wrong intervention: Plan was not personalised.
Lahdensuo 1996 Wrong comparator: PAAP plus education (therapeutic counselling by specialist nurses and relaxation/breath-
ing techniques by physiotherapist) vs general asthma advice by specialist nurse and no PAAP
Levy 1995 Wrong comparator: PAAP plus education provided by secondary care specialist nurses at arranged consulta-
tions vs usual care in primary care setting
Lincicome 2001 Wrong participant population: paediatric participants aged 3 to 15 years
Magar 2005 Wrong comparator: PAAP plus education vs no PAAP and no education
McLean 2003 Wrong comparator: PAAP plus education vs no PAAP and no education
NCT00129662 Wrong study design: non-randomised study.
NCT00214669 2005 Wrong comparator: PAAP plus education vs no PAAP and no education
NCT01070095 Wrong study design: non-randomised, single group assignment.
NCT01079000 2012 Wrong comparator: Control group received PAAP.
NCT01282359 Wrong comparator: PAAP plus education vs no PAAP and no education
NCT02046759 Wrong comparator: PAAP plus education vs no PAAP and no education
NCT02091869 2014 Wrong participant population: paediatric patients aged 12 to 17 years
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Olivera 2016 Wrong comparator: education (and possibly PAAP) vs no education and no PAAP
Osman 2001 Wrong comparator: 30% of control group also received a PAAP.
Parkes 2012 Wrong study design: non-randomised (study authors contacted and confirmed that randomised portion of
study will not go ahead)
Patel 2015 Wrong comparator: PAAP plus education vs no PAAP and no education
Put 2001 Wrong intervention: workbook to re-enforce education (not PAAP)
Ross 2012 Wrong intervention: no reference to use of a PAAP.
Sittipunt 2008 Wrong comparator: PAAP plus education vs no PAAP and no education
Steurer-Stey 2010 Wrong comparator: Control group also received a PAAP.
Tousman 2009 Wrong intervention: daily tracking diary rather than a PAAP.
Tuazon 2000 Wrong comparator: comparison between 2 different education programmes. Unsure about inclusion of a
PAAP
Urek 2005 Wrong intervention: comparison of 3 different education approaches
Wilson-Pessano 1987 Wrong intervention: no reference to PAAP.
Zairina 2015 Wrong intervention: tele-health application.
Characteristics of studies awaiting assessment [ordered by study ID]
Angelini 2010
Methods Study design: randomised controlled trial with 3 parallel groups: control, education and self-management
Total duration of study: 24 months.
Details of any ’run-in’ period: not reported.
Number of centres and locations: not reported.
Study setting: not reported.
Withdrawals: not reported.
Date of study: not reported.
Participants Number of participants: 84.
Mean age: not reported.
Age range: not reported.
Gender: not reported.
Severity of condition: “moderate and severe persistent asthma”.
Diagnostic criteria: not reported.
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Baseline lung function: not reported.
Smoking history: not reported.
Study inclusion criteria: not reported.
Study exclusion criteria: not reported.
Interventions Intervention: educational programme consisting of lectures on pathophysiology and environmental control, asthma
symptoms, treatment and training in the inhalation technique. Self-management group also received a symptoms
diary card and a written personal asthma action plan
Comparison: not reported.
Concomitant medications and excluded medications: not reported.
Outcomes Primary outcomes: Asthma Control Test (mean score).
Secondary outcomes:Questionnaire Disease Knowledge (QDK), asthma quality of life (AQLQ-s), Hospital Anxiety
and Depression Scale (HADS), functional literacy health test (s-TOFHLA). (Study authors do not distinguish
between primary and secondary.)
Notes Funding for trial: not reported.
Notable conflicts of interest of trial authors: not reported.
Correspondence with trial authors: none.
Characteristics of ongoing studies [ordered by study ID]
NCT02190617 2014
Trial name or title Guidelines to Practice: Reducing Asthma Health Disparities Through Guideline Implementation
Methods Randomised controlled trial, intervention study.
Participants Aged 5 to 75 years with a diagnosis of uncontrolled asthma; estimated enrolment 550
Interventions 1. Enhanced clinic plus unified management plan; 2. Home visit option only; 3. Enhanced clinic plus unified
management plan plus home visit option
Outcomes Symptom-free days, asthma control, asthma-related quality of life, nocturnal awakening, asthma exacerba-
tions, pulmonary function, fractional exhaled nitric oxide, beta-agonist use, oral steroid use, controller use,
emergency healthcare utilisation, days of work or school missed, general health status
Starting date December 2014.
Contact information James Stout, MD (Washington University).
Notes https://clinicaltrials.gov/show/NCT02190617
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NCT02424409 2015
Trial name or title Evaluation of the Relapse Rate One Month After Discharge From Emergency Department for Asthmatic
Patients Given a Strict Formalized Follow up Protocol
Methods Randomised controlled trial, intervention study.
Participants Patients over 18 years, consulting to the emergency department for an acute asthma attack, who, after initial
treatment are discharged directly from the emergency department after giving free and informed consent
Interventions Personalised asthma action plan (PAAP) vs no PAAP.
Outcomes Recurrence rate of any asthma attacks at 15 days and at 1 month, hospitalisation rate at 30 days, asthma
control score, percentage of participants self-medicating, percentage of participants using peak flow meter,
participant adherence to protocol
Starting date August 2015.
Contact information Jennifer Truchot, MD; jennifer.truchot@lrb.aphp.fr.
Notes https://clinicaltrials.gov/ct2/show/NCT02424409
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D A T A A N D A N A L Y S E S
Comparison 1. PAAP versus no PAAP
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1Number of participants reporting
at least 1 exacerbation requiring
emergency department visit or
hospitalisation
5 1385 Odds Ratio (M-H, Random, 95% CI) 0.75 [0.45, 1.24]
2 Asthma symptom scores (change
from baseline in ACQ)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
3 Serious adverse events (including
deaths)
1 Odds Ratio (M-H, Random, 95% CI) Subtotals only
4 Quality of life (change from
baseline in AQLQ)
3 441 Mean Difference (IV, Random, 95% CI) 0.18 [0.05, 0.30]
5Number of participants reporting
at least 1 exacerbation requiring
systemic corticosteroids
3 1136 Odds Ratio (M-H, Random, 95% CI) 1.45 [0.84, 2.48]
6 Measure of respiratory function
(change from baseline in FEV1
(L))
3 392 Mean Difference (IV, Random, 95% CI) -0.04 [-0.25, 0.17]
7 Measure of respiratory function
(change from baseline in %
predicted FEV1)
2 146 Mean Difference (IV, Random, 95% CI) 0.40 [-6.05, 6.85]
8 Measure of respiratory function
(change from baseline in %
predicted PEF)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
9 Measure of respiratory function
(change from baseline in PEF
(L/min))
1 Mean Difference (IV, Random, 95% CI) Totals not selected
10 Days lost from work or study 1 74 Mean Difference (IV, Random, 95% CI) -6.2 [-7.32, -5.08]
Comparison 2. PAAP plus education versus education alone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1Number of participants reporting
at least 1 exacerbation requiring
emergency department visit or
hospitalisation
1 Odds Ratio (Fixed, 95% CI) Subtotals only
2 Asthma symptom scores (change
from baseline in ACQ score)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
3 Quality of life (change from
baseline in AQLQ score)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
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4Number of participants reporting
at least 1 exacerbation requiring
systemic corticosteroids
1 Odds Ratio (Random, 95% CI) Subtotals only
WH A T ’ S N E W
Date Event Description
12 April 2017 Amended AR affiliation and COI statement corrected.
C O N T R I B U T I O N S O F A U T H O R S
All review authors contributed to drafting of the protocol, reviewed it critically for intellectual content, provided final approval of the
version to be published and are accountable for all aspects of the work.
D E C L A R A T I O N S O F I N T E R E S T
David Evans: provides freelance medical writing services to medical communications agencies.
Alison Rushton: undertook a feasibility study to pilot a locally developed asthma self-management plan for children and young people
within a Clinical Commissioning Group (CCG) locality in the northwest of England. The project was completed in 2015 as part of
a Clinical Academic Internship, funded by Health Education England and a northwest CCG. The intern received no payment for
including individuals in the study.
Nathan Halcovitch: none.
Fiona Eccles: none.
Timothy Gatheral: none.
Sally Spencer: serves as co-investigator on the Cochrane Programme Grant supporting this review.
Gemma Whiteley: none.
Caroline Mulvaney: none.
S O U R C E S O F S U P P O R T
Internal sources
• The review authors declare that no funding was received for this protocol, Other.
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External sources
• Alison Rushton, Nathan Halcovitch, Timothy Gatheral, Gemma Whiteley declare that no such funding was received for this
review, Other.
• David Evans, UK.
National Institute for Health Research: Evidence to guide care in adults and children with asthma, 13/89/14
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In the original protocol, we stated that “If a study uses more than one scale to report the same outcome, or if different scales were used
across studies, we will analyse them together using the standardised mean difference.” For quality of life outcomes reported on different
scales across individual studies, we reported outcomes separately, as combining scales using the standardised mean difference would be
clinically difficult to interpret.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Patient Education as Topic; Asthma [complications; ∗drug therapy; mortality]; Disease Progression; Emergency Medical Services
[statistics & numerical data]; Hospitalization [statistics & numerical data]; Quality of Life; Randomized Controlled Trials as Topic;
Self Care [adverse effects; ∗methods; mortality]
MeSH check words
Adult; Humans; Middle Aged
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